<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>IgA Nephropathy Insights</title>
    <description>Your patient and practitioner news, research and digital healthcare source</description>
    
    <link>https://iga-nephropathy.beehiiv.com/</link>
    <atom:link href="https://rss.beehiiv.com/feeds/o22h1lsiRo.xml" rel="self"/>
    
    <lastBuildDate>Tue, 3 Mar 2026 00:48:26 +0000</lastBuildDate>
    <pubDate>Wed, 30 Apr 2025 18:00:00 +0000</pubDate>
    <atom:published>2025-04-30T18:00:00Z</atom:published>
    <atom:updated>2026-03-03T00:48:26Z</atom:updated>
    
      <category>Health</category>
      <category>Healthcare</category>
    <copyright>Copyright 2026, IgA Nephropathy Insights</copyright>
    
    <image>
      <url>https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/publication/logo/01505377-41dc-4ba4-942e-8c36bf3f7081/Icon_Blue.png</url>
      <title>IgA Nephropathy Insights</title>
      <link>https://iga-nephropathy.beehiiv.com/</link>
    </image>
    
    <docs>https://www.rssboard.org/rss-specification</docs>
    <generator>beehiiv</generator>
    <language>en-us</language>
    <webMaster>support@beehiiv.com (Beehiiv Support)</webMaster>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>Our research summaries provide insights into the latest scientific...</description>
  <link>https://iga-nephropathy.beehiiv.com/p/29042025</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/29042025</guid>
  <pubDate>Wed, 30 Apr 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-04-30T18:00:00Z</atom:published>
    <category><![CDATA[Newsletter]]></category>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: #f6f4f2; overflow: hidden; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><tr><td style="padding: 15px 0px;"><div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin: 0; padding: 20px; border-radius: 8px;"><div style="color: rgb(48,44,42); text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><p style="margin: 0 0 15px 0; line-height: 1.6;">Our research summaries provide insights into the latest scientific developments. Check back in our next newsletter for updates.</p></div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Clinical Trials</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin: 0 20px 25px; text-align: justify; color: rgb(48,44,42); font-size: 16px; line-height: 1.6;"> This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks: </div><div style="margin: 0 20px;"><a href="https://clinicaltrials.gov/study/NCT04557462?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">34 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18 - 100 Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">540</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06564142?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">27 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">480</div></td></tr></table></div></a><div style="text-align: left; margin-top: 30px; margin-bottom: 20px;"><a href="https://clinicaltrials.gov/search?cond=IgA%20Nephropathy&aggFilters=status:rec&utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=all-trials" rel="noopener noreferrer" style="color: rgb(6,125,143); text-decoration: none; font-weight: bold; font-size: 15px;" target="_blank"> View the full list of clinical trials → </a></div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Community News</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.facebook.com/1093537322817808/posts/1098491645655709?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=personal-stories" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="Kidney Research UK" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/7499506606.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">Kidney Research UK</strong><span style="color: #999; font-size: 14px; display: block;">Apr 28, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">After younger brother, George, was diagnosed with IgA nephropathy in 2023, Ed was a match and donated his kidney in February 2024.<br/><br/>George says: “Going to hospital became my whole life, I was there numerous times a week and my kidney function kept falling rapidly.<br/><br/>“It was heartbreaking seeing my test results constantly getting worse and not knowing what that meant for my future. It changed my outlook on what is important in life, and I will always be thankful for the support I received from friends and family.”<br/><br/>Ed says: “By the time our transplant happened, we had become very comfortable with needles and medical equipment throughout the matching process. It just felt straightforward to go and get the transplant done.<br/><br/>“It felt rough for a few weeks post-surgery, but the transplant has been a resounding success. George’s new kidney immediately started filtering his blood and continues to function well. He’s been able to get back to work and move forward with his life. For me, after the initial recovery from surgery, I’ve not had any problems whatsoever.”<br/><br/>Ed and wife, Izzy, have supported other kidney patients, by taking part in the Richmond Ultra-Marathon raising over £8,500!<br/><br/>Read their full story here: <strong style="color: rgb(6,125,143);">https://bit.ly/3EI3aWt</strong><br/><br/>[Image description: 1 – Ed and George pose for a photo outside NHS Hammersmith Hospital. One wears a black top, grey tracksuit bottoms, white trainers, and has short, light hair. The other has on a grey top, black tracksuit bottoms, Nike trainers, and sports a dark beard with a mullet-style haircut. Both are carrying overnight bags. Behind them is a directions board welcoming visitors to ‘Area F’.<br/><br/>2 – A black and white professional photo captures Ed and George embracing and smiling at a wedding. They’re both in white shirts and black trousers. The background is softly blurred, showing wedding guests, fairy lights, foliage around a wedding arch, and the interior of a tipi tent.<br/><br/>3 – Another black and white professional wedding photo shows Ed and George sitting on guests' shoulders, singing along to a song. They’re the focus of the lively group shot, surrounded by guests with hands in the air. Both are wearing white shirts and black trousers, with fairy lights, foliage, and the tipi tent interior visible behind them.]</p></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><a href="https://www.facebook.com/1093758122784071/posts/1099036698922880?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=personal-stories" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="NephCure" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/84026010805.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">NephCure</strong><span style="color: #999; font-size: 14px; display: block;">Apr 28, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">Meet Stacey, who at the age of 5, was diagnosed with childhood nephrotic syndrome that was later diagnosed as minimal change disease in 2019.<br/><br/>Stacey moved shortly after her initial diagnosis as a child, and following her first or second relapse, the pediatrician referred her to a pediatric nephrologist. After extensive testing, the specialist allowed the local pediatrician to manage her relapses. In 1979, Stacey's family relocated to Texas, where their family doctor promptly referred her to Children's Medical Center in Dallas for additional testing. She continued receiving steroid treatments for her relapses. Eventually, these episodes became less frequent, occurring approximately twice a year, and ceased entirely around age 13. From ages 5 through 12, Stacey's treatment consisted exclusively of steroids.<br/><br/>In 1990, Stacey experienced what doctors believed was a relapse. Her mother took her to a nephrologist who performed a renal biopsy, though they don't recall the results or recommendations, and her records have since been destroyed.<br/><br/>Between ages 20 and 48, Stacey remained relapse-free. In 2018, she began noticing pitting edema on her shins at day's end, attributing it to normal aging, though it worsened after long flights and never fully disappeared.<br/><br/>Around Labor Day 2018, she developed severe pain in her side and shoulder, especially when breathing deeply. After enduring it for days with sleepless nights, she visited an urgent care clinic. X-rays and an electrocardiogram indicated possible mild pneumonia or rib injury. She received antibiotics and a Medrol pack.<br/><br/>Concerned about a potential kidney connection due to her mother's history of childhood nephrotic syndrome, FSGS, dialysis, and kidney transplant, Stacey consulted her doctor. Though the doctor attributed the water retention to steroids, blood tests were ordered to check kidney function before prescribing a diuretic.<br/><br/>Stacey continued experiencing pain and sleeplessness. After another doctor visit and x-ray, she received a second antibiotic for suspected pneumonia. The pain while reclining persisted for months, and the water retention never fully resolved. She struggled to resume running due to swollen legs but persisted to try eliminating excess fluid.<br/><br/>Concerned about the persistent edema, Stacey experimented with various diets—no salt, fasting, high protein/low carb—but saw no improvement. During online research, she discovered Adult Nephrotic Syndrome and Minimal Change Disease, conditions she hadn't previously connected to her symptoms.<br/><br/>At her next checkup, Stacey requested tests for blood protein levels and urinary protein. When initially told her bloodwork looked good except for needing more protein, she inquired about her urinalysis. After a delayed response confirming protein in her urine, she was asked to provide another sample but instead sought a specialist.<br/><br/>Fortunately, she quickly secured an appointment with a nephrologist who confirmed her suspicions. A February 2019 biopsy revealed Minimal Change Disease (MCD), beginning her journey of relapses and medication adjustments. Though challenging, Stacey considers herself fortunate—she's avoided hospitalization, generally responds to treatment, maintains an active lifestyle, and found support through NephCure and Facebook kidney disease groups.<br/><br/>To read more stories like Stacey's, visit <strong style="color: rgb(6,125,143);">NephCure.org!</strong></p></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><a href="https://www.facebook.com/1103813471790744/posts/1105783988260359?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=policy-and-regulation" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="National Kidney Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/35677414105.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">National Kidney Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Apr 24, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">NKF is urging committee members to reject Medicaid cuts that would harm people with kidney disease. The kidney patient community is particularly vulnerable to changes in coverage, as consistent access to care is literally life-sustaining. <strong style="color: rgb(6,125,143);">#MyKidneyVoice</strong></p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="National Kidney Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250429-1" style="width: 100%; height: auto; display: block;"/></div></div></a><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Upcoming Events</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div></td></tr><tr><td><table style="width: 100%; max-width: 600px; margin-bottom: 28px; padding-top: 20px; border: none; border-collapse: separate; overflow: hidden;"><tr><td rowspan="1" style="width: 110px; text-align: center; vertical-align: top; padding: 0; border: none; padding-bottom: 40px;"><table style="width: 110px; border: 3px solid rgb(6,125,143); border-radius: 18px; background: #f6f4f2; border-collapse: separate; overflow: hidden;"><tr><td style="background: rgb(6,125,143); color: white; text-align: center; padding: 8px 0; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; border-radius: 15px 15px 0 0; font-size: 16px;"> MAY </td></tr><tr><td style="text-align: center; padding: 8px 0; font-size: 36px; font-weight: bold; color: rgb(6,125,143); font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> 01 </td></tr></table></td><td style="padding: 0 0 40px 20px; border: none; vertical-align: top;"><div style="margin: 0;"><span style="display: block; color: rgb(48,44,42); font-size: 20px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><strong style="display: inline-block; margin-right: 10px;">37-mile challenge for kidney patients</strong><span style="display: inline-block; vertical-align: middle;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/online2.png" style="width: 16px; height: 18px; margin: 0 0 0 6px; vertical-align: middle;"/><span style="color: rgb(6,125,143); vertical-align: middle; font-size: 16px;"> Online</span></span></span><span style="display: block; color: #666; font-size: 16px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> American Kidney Fund </span><div style="margin-top: 12px;"><a href="https://www.facebook.com/993556066304463/videos/539267405635071?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=fundraising" rel="noopener noreferrer" style="display: inline-flex; align-items: center; padding: 8px 16px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; margin-right: 12px; transition: all 0.2s ease; border: 2px solid rgb(6,125,143);" target="_blank"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/info.png" style="width: 16px; height: 16px; margin-right: 6px;"/> More Info </a><a href="https://healthspotlight-newsletters.s3.amazonaws.com/calendar_events/37-mile_challenge_for_kidney_patients-american_kidney_fund-20250501.ics?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=fundraising" style="display: inline-flex; align-items: center; padding: 8px 16px; border: 2px solid rgb(6,125,143); color: rgb(6,125,143); text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; transition: all 0.2s ease;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/calendar2.png" style="width: 16px; height: 16px; margin-right: 6px;"/> Add to Calendar </a></div></div></td></tr></table></td></tr></div></td></tr></table><tr><td style="padding: 15px 0;"></td></tr><tr><td style="padding: 0 0 20px 0;"><div style="text-align: center;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-right: -5px;"></div><a href="https://www.allmyhealth.io/our-communities/iga-nephropathy?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="display: inline-block; padding: 8px 16px; background-color: white; color: rgb(6,125,143); text-decoration: none; border-radius: 10px; font-family: Roboto, Arial, sans-serif; font-size: 14px; border: 1px solid rgb(6,125,143); margin: 0; font-weight: bold;" target="_blank"> Subscribe </a><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-left: -5px;"></div></div></td></tr></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=b00c5f20-04df-4ee1-9c11-a11efffd493a&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>Treatment Advances and KDIGO Guidelines Shape IgA Nephropathy Care</description>
  <link>https://iga-nephropathy.beehiiv.com/p/22042025</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/22042025</guid>
  <pubDate>Wed, 23 Apr 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-04-23T18:00:00Z</atom:published>
    <category><![CDATA[Newsletter]]></category>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: #f6f4f2; overflow: hidden; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Top Stories</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.ajmc.com/view/overview-of-treatment-landscape-for-iga-nephropathy-standard-of-care-and-kdigo-guidelines?utm_source=iga-nephropathy-insights&utm_content=news" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgb(235,232,230); border-left: 4px solid rgb(6,125,143); transition: background 0.2s ease;"><div style="color: rgb(48,44,42); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">Treatment Advances and KDIGO Guidelines Shape IgA Nephropathy Care</div><div style="margin: 0; line-height: 1.6; color: #444; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Recent developments in IgA nephropathy management emphasize tailored treatment based on disease severity, combining supportive care like blood pressure control with new targeted therapies approved to reduce kidney damage and progression risk. Guidelines recommend personalizing therapy to balance benefits and side effects.</div><span style="color: rgb(6,125,143); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a><a href="https://www.ajmc.com/view/clinical-impact-of-iga-nephropathy-and-quality-of-life?utm_source=iga-nephropathy-insights&utm_content=news" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgb(235,232,230); border-left: 4px solid rgb(6,125,143); transition: background 0.2s ease;"><div style="color: rgb(48,44,42); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">Clinical Impact of IgA Nephropathy on Patient Quality of Life and Kidney Health</div><div style="margin: 0; line-height: 1.6; color: #444; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">IgA nephropathy affects patients through ongoing symptoms, treatment challenges, and mental health impacts, while the risk of worsening kidney function highlights the need for early treatment and supportive care to improve life quality and slow disease progression.</div><span style="color: rgb(6,125,143); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin: 0; padding: 20px; border-radius: 8px;"><div style="color: rgb(48,44,42); text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><p style="margin: 0 0 15px 0; line-height: 1.6;">A recent case report describes a 61-year-old woman with type 1 diabetes who experienced rapid kidney function deterioration due to rapidly progressive IgA nephropathy following a SARS-CoV-2 vaccination. <a href="https://link.springer.com/article/10.1007/s13730-025-00993-4?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="color: rgb(6,125,143) !important; text-decoration: none;" target="_blank"><span style="color: rgb(6,125,143);"><strong>Masaki et al. (2025)</strong></span></a> This condition was successfully treated with cyclophosphamide, a medication used to reduce inflammation and slow disease progression in severe kidney disease cases.<br/><br/> The case highlights the potential for IgA nephropathy to cause significant kidney issues, even in individuals with pre-existing conditions like diabetes. Aggressive medical intervention, such as cyclophosphamide, can be effective in managing severe kidney disease flare-ups, as seen in this case <a href="https://link.springer.com/article/10.2025/s20250-025-20253-4?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="color: rgb(6,125,143) !important; text-decoration: none;" target="_blank"><span style="color: rgb(6,125,143);"><strong>(Masaki et al., 2025)</strong></span></a>.</p></div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Clinical Trials</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin: 0 20px 25px; text-align: justify; color: rgb(48,44,42); font-size: 16px; line-height: 1.6;"> This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks: </div><div style="margin: 0 20px;"><a href="https://clinicaltrials.gov/study/NCT06564142?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">27 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">480</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT05852938?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> A Study of Zigakibart in Adults With IgA Nephropathy </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">23 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">292</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06712407?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iv" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgb(4,95,108); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase IV</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">United States</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">60</div></td></tr></table></div></a><div style="text-align: left; margin-top: 30px; margin-bottom: 20px;"><a href="https://clinicaltrials.gov/search?cond=IgA%20Nephropathy&aggFilters=status:rec&utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=all-trials" rel="noopener noreferrer" style="color: rgb(6,125,143); text-decoration: none; font-weight: bold; font-size: 15px;" target="_blank"> View the full list of clinical trials → </a></div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Community News</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.facebook.com/1093537322817808/posts/1090556569782550?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=fundraising-and-events" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="Kidney Research UK" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/7499506606.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">Kidney Research UK</strong><span style="color: #999; font-size: 14px; display: block;">Apr 18, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">After leaving her life in New Zealand, Jennie is running in the TCS London Marathon following her decision to donate a kidney to her twin sister, Sue, who was diagnosed with IgA nephropathy in 2017.<br/><br/>“Sue is a bright and bubbly person, but as her kidney function declined, she began feeling cold and tired with persistent headaches. She’d lost her spark and was very unwell. I didn’t think twice about donating my kidney. I don’t need two, and it has made a huge difference to Sue’s life.<br/><br/>“It was hard going through so many ups and downs, but being motivated by love for my sister kept me going. The testing process was challenging, but I had no worries about the operation itself, and my recovery was quick.<br/><br/>“For Sue it has been transformative. She has twin daughters, and they wrote a lovely message about how nice it has been to have their mum back. She has had a new lease of life.<br/><br/>“I’m excited and terrified about running the marathon! I’m just following my training plan as best I can. It will be great to have the support of Sue and the rest of the family cheering me on the day.<br/><br/>“I want to help fund research. It seems crazy to me that both my sister and brother-in-law have the same disease, but we don’t know the causes. Nobody can tell us how or why it has happened. If researchers can better understand that, maybe we can stop it and put an end to kidney disease.”<br/><br/>Read the full story here: <strong style="color: rgb(6,125,143);">https://bit.ly/4ikAAbB</strong><br/><br/>[Image description: 1 – Jennie and Sue are sitting in a hospital room. Between them is a small table with drinks, paperwork, medicine and a flower. Both of them are smiling at the camera. One is in a blue and white polka dot dressing gown and the other is in a hospital gown with tubes coming out of their body. Behind them is a hospital bed and sink.<br/><br/>2 – Jennie and Sue posing for a selfie, standing close together, on a sunny day in a forest. The sun is shining on their faces with the shadows of trees visible on them. Behind them are big trees, fern bushes, and bluebells. They both have straight blonde hair and are wearing casual t shirts and jackets.<br/><br/>3 – Jennie and Sue posing for a photo smiling. They appear to be on holiday in a hat or gift shop. They are both wearing straw hats, with other hats visible in the background. One is wearing a royal blue dress, white bag, and dark sunglasses are hanging on the neckline of the dress. The other is wearing a light pink dress with black and red leopard spots all over. They both have curtly blonde hair.<br/><br/>4 – Jennie and Sue posing for a photo on a beautiful sunny day. Behind them is Waiau river bridge, Hammer Springs in New Zealand. The river is a blue, green colour, and all the trees, plants, and grass in the background are lush green. Both of them are smiling with sunglasses on their heads. One is in light blue jeans, a black top and jumper and the other is in black jeans, a white knitted jumper and a white sleeveless gilet.]</p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="Kidney Research UK Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250422-1" style="width: 100%; height: auto; display: block;"/></div></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><a href="https://www.facebook.com/1103813471790744/posts/1098548848983873?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=donation-appeal" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="National Kidney Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/35677414105.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">National Kidney Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Apr 15, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">Almost 30% of donor kidneys are discarded every year and that number has been on the rise. It’s time to reimagine our transplant system and ensure that everyone who needs a kidney can get one. <strong style="color: rgb(6,125,143);">#TransplantsForAll</strong><strong style="color: rgb(6,125,143);">#DonateLifeMonth</strong><strong style="color: rgb(6,125,143);">https://bit.ly/4cn5q1Z</strong></p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="National Kidney Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250422-2" style="width: 100%; height: auto; display: block;"/></div></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><a href="https://www.facebook.com/993556066304463/posts/989466473380089?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=patient-resources" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="American Kidney Fund" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/44224524016.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">American Kidney Fund</strong><span style="color: #999; font-size: 14px; display: block;">Apr 16, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">Did you know that autosomal dominant polycystic kidney disease (ADPKD) is the most common type of polycystic kidney disease (PKD)? ADPKD causes cysts to grow in the kidneys and occurs in 9 out of every 10 people with PKD. Learn more about signs, symptoms and treatment options for ADPKD: <strong style="color: rgb(6,125,143);">https://bit.ly/42ilUnv</strong></p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="American Kidney Fund Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250422-3" style="width: 100%; height: auto; display: block;"/></div></div></a><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Upcoming Events</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div></td></tr><tr><td><table style="width: 100%; max-width: 600px; margin-bottom: 28px; padding-top: 20px; border: none; border-collapse: separate; overflow: hidden;"><tr><td rowspan="1" style="width: 110px; text-align: center; vertical-align: top; padding: 0; border: none; padding-bottom: 40px;"><table style="width: 110px; border: 3px solid rgb(6,125,143); border-radius: 18px; background: #f6f4f2; border-collapse: separate; overflow: hidden;"><tr><td style="background: rgb(6,125,143); color: white; text-align: center; padding: 8px 0; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; border-radius: 15px 15px 0 0; font-size: 16px;"> JUL </td></tr><tr><td style="text-align: center; padding: 8px 0; font-size: 36px; font-weight: bold; color: rgb(6,125,143); font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> 23 </td></tr></table></td><td style="padding: 0 0 40px 20px; border: none; vertical-align: top;"><div style="margin: 0;"><span style="display: block; color: rgb(48,44,42); font-size: 20px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><strong style="display: inline-block; margin-right: 10px;">Rare Kidney Disease Advocacy</strong><span style="display: inline-block; vertical-align: middle;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/inperson2.png" style="width: 16px; height: 18px; margin: 0 0 0 6px; vertical-align: middle;"/><span style="color: rgb(6,125,143); vertical-align: middle; font-size: 16px;"> In Person</span></span></span><span style="display: block; color: #666; font-size: 16px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> NephCure </span><div style="margin-top: 12px;"><a href="https://www.facebook.com/1093758122784071/posts/1088066170019933?utm_source=iga-nephropathy-insights&utm_content=in-person-event&utm_topic=advocacy" rel="noopener noreferrer" style="display: inline-flex; align-items: center; padding: 8px 16px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; margin-right: 12px; transition: all 0.2s ease; border: 2px solid rgb(6,125,143);" target="_blank"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/info.png" style="width: 16px; height: 16px; margin-right: 6px;"/> More Info </a><a href="https://healthspotlight-newsletters.s3.amazonaws.com/calendar_events/rare_kidney_disease_advocacy-nephcure-20250723.ics?utm_source=iga-nephropathy-insights&utm_content=in-person-event&utm_topic=advocacy" style="display: inline-flex; align-items: center; padding: 8px 16px; border: 2px solid rgb(6,125,143); color: rgb(6,125,143); text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; transition: all 0.2s ease;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/calendar2.png" style="width: 16px; height: 16px; margin-right: 6px;"/> Add to Calendar </a></div></div></td></tr></table></td></tr></div></td></tr></table><tr><td style="padding: 15px 0;"></td></tr><tr><td style="padding: 0 0 20px 0;"><div style="text-align: center;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-right: -5px;"></div><a href="https://www.allmyhealth.io/our-communities/iga-nephropathy?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="display: inline-block; padding: 8px 16px; background-color: white; color: rgb(6,125,143); text-decoration: none; border-radius: 10px; font-family: Roboto, Arial, sans-serif; font-size: 14px; border: 1px solid rgb(6,125,143); margin: 0; font-weight: bold;" target="_blank"> Subscribe </a><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-left: -5px;"></div></div></td></tr></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=6e95edd3-e18e-450f-8e1f-7006a1825543&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>Sparsentan Reduces Proteinuria in IgA Nephropathy</description>
  <link>https://iga-nephropathy.beehiiv.com/p/15042025</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/15042025</guid>
  <pubDate>Wed, 16 Apr 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-04-16T18:00:00Z</atom:published>
    <category><![CDATA[Newsletter]]></category>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: #f6f4f2; overflow: hidden; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Top Stories</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.healio.com/news/nephrology/20250410/firstline-sparsentan-use-associated-with-proteinuria-reduction-in-iga-nephropathy?utm_source=iga-nephropathy-insights&utm_content=news&utm_topic=pharmaceutical-insights" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgb(235,232,230); border-left: 4px solid rgb(6,125,143); transition: background 0.2s ease;"><div style="color: rgb(48,44,42); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">Sparsentan Reduces Proteinuria in IgA Nephropathy</div><div style="margin: 0; line-height: 1.6; color: #444; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Using sparsentan as a first-line treatment can significantly reduce excessive protein in the urine for people with IgA Nephropathy, potentially slowing kidney damage.</div><span style="color: rgb(6,125,143); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin: 0; padding: 20px; border-radius: 8px;"><div style="color: rgb(48,44,42); text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><p style="margin: 0 0 15px 0; line-height: 1.6;">There is no direct information available about the specific article titled "Association of Ultrasound Quadriceps Muscle Thickness with Frailty among Hemodialysis Patients. <a href="https://journals.ekb.eg/article_422050_0.html?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="color: rgb(6,125,143) !important; text-decoration: none;" target="_blank"><span style="color: rgb(6,125,143);"><strong>Ismail et al. (2025)</strong></span></a>" However, the study likely explores how muscle thickness, as measured by ultrasound, relates to frailty in patients undergoing hemodialysis. This could involve examining how muscle health impacts overall well-being and disease outcomes in these patients.<br/><br/> IgA nephropathy is a condition characterized by IgA deposits in the kidneys, leading to inflammation and potential kidney failure over time. Symptoms include blood in the urine and swelling. While there is no cure, treatments can slow disease progression. For more on chronic kidney disease outcomes, research like that of frailty among hemodialysis patients is relevant, though specific findings from the mentioned article are not available.</p></div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Clinical Trials</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin: 0 20px 25px; text-align: justify; color: rgb(48,44,42); font-size: 16px; line-height: 1.6;"> This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks: </div><div style="margin: 0 20px;"><a href="https://clinicaltrials.gov/study/NCT06740526?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-ii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,0.75); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase II</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">2 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">16+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">25</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06564142?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">27 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">480</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT05852938?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> A Study of Zigakibart in Adults With IgA Nephropathy </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">23 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">292</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06712407?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iv" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgb(4,95,108); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase IV</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">United States</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">60</div></td></tr></table></div></a><div style="text-align: left; margin-top: 30px; margin-bottom: 20px;"><a href="https://clinicaltrials.gov/search?cond=IgA%20Nephropathy&aggFilters=status:rec&utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=all-trials" rel="noopener noreferrer" style="color: rgb(6,125,143); text-decoration: none; font-weight: bold; font-size: 15px;" target="_blank"> View the full list of clinical trials → </a></div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Community News</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.facebook.com/955913750072294/videos/634827629372234?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=personal-stories" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Apr 14, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">🎥 Meet Amanda L., one of our inspiring IgA Nephropathy Foundation Ambassadors!<br/><br/>She’s navigating life as a post-transplant IgAN warrior with grit, grace—and a splash of creativity. Hailing from Bensalem, PA, Amanda is not only an artist but also an axe and knife thrower. (Yes, you read that right!)<br/><br/>Watch her share her story and how she stays empowered after transplant.</p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="IgA Nephropathy Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250415-1" style="width: 100%; height: auto; display: block;"/></div></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><a href="https://www.facebook.com/955913750072294/posts/1011304807866521?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=fundraising-and-events" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Apr 11, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">❤️💙 DON’T MISS OUT ON YOUR OPPORTUNITY TO CONNECT ⁠<br/><br/>We invite you to join our monthly virtual IgAN Support Groups! We hold these virtually on the third Mon/Tues of every month to give IgAN patients and care partners an opportunity to meet each other and share their journeys.⁠<br/><br/>⁠<br/><br/>⁠[Virtual] Caregiver|CarePartner Support Call⁠<br/><br/>Tuesday, April 15th 7PM ET⁠<br/><br/>⁠<br/><br/>⁠[Virtual] Patient Support Group⁠<br/><br/>Monday, April 21st 7PM ET⁠<br/><br/>⁠<br/><br/>⁠<br/><br/>Full schedule of upcoming support groups and other events at <strong style="color: rgb(6,125,143);">igan.org/events</strong></p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="IgA Nephropathy Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250415-2" style="width: 100%; height: auto; display: block;"/></div></div></a><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Upcoming Events</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div></td></tr><tr><td><table style="width: 100%; max-width: 600px; margin-bottom: 28px; padding-top: 20px; border: none; border-collapse: separate; overflow: hidden;"><tr><td rowspan="1" style="width: 110px; text-align: center; vertical-align: top; padding: 0; border: none; padding-bottom: 40px;"><table style="width: 110px; border: 3px solid rgb(6,125,143); border-radius: 18px; background: #f6f4f2; border-collapse: separate; overflow: hidden;"><tr><td style="background: rgb(6,125,143); color: white; text-align: center; padding: 8px 0; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; border-radius: 15px 15px 0 0; font-size: 16px;"> APR </td></tr><tr><td style="text-align: center; padding: 8px 0; font-size: 36px; font-weight: bold; color: rgb(6,125,143); font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> 16 </td></tr></table></td><td style="padding: 0 0 40px 20px; border: none; vertical-align: top;"><div style="margin: 0;"><span style="display: block; color: rgb(48,44,42); font-size: 20px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><strong style="display: inline-block; margin-right: 10px;">Social Media for Kidney Donors</strong><span style="display: inline-block; vertical-align: middle;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/online2.png" style="width: 16px; height: 18px; margin: 0 0 0 6px; vertical-align: middle;"/><span style="color: rgb(6,125,143); vertical-align: middle; font-size: 16px;"> Online</span></span></span><span style="display: block; color: #666; font-size: 16px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> IgA Nephropathy Foundation • Wall, NJ </span><div style="margin-top: 12px;"><a href="https://www.facebook.com/955913750072294/posts/1009483061382029?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=educational" rel="noopener noreferrer" style="display: inline-flex; align-items: center; padding: 8px 16px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; margin-right: 12px; transition: all 0.2s ease; border: 2px solid rgb(6,125,143);" target="_blank"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/info.png" style="width: 16px; height: 16px; margin-right: 6px;"/> More Info </a><a href="https://healthspotlight-newsletters.s3.amazonaws.com/calendar_events/social_media_for_kidney_donors-iga_nephropathy_foundation-20250416.ics?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=educational" style="display: inline-flex; align-items: center; padding: 8px 16px; border: 2px solid rgb(6,125,143); color: rgb(6,125,143); text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; transition: all 0.2s ease;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/calendar2.png" style="width: 16px; height: 16px; margin-right: 6px;"/> Add to Calendar </a></div></div></td></tr><tr><td rowspan="1" style="width: 110px; text-align: center; vertical-align: top; padding: 0; border: none; padding-bottom: 40px;"><table style="width: 110px; border: 3px solid rgb(6,125,143); border-radius: 18px; background: #f6f4f2; border-collapse: separate; overflow: hidden;"><tr><td style="background: rgb(6,125,143); color: white; text-align: center; padding: 8px 0; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; border-radius: 15px 15px 0 0; font-size: 16px;"> SEP </td></tr><tr><td style="text-align: center; padding: 8px 0; font-size: 36px; font-weight: bold; color: rgb(6,125,143); font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> 27 </td></tr></table></td><td style="padding: 0 0 40px 20px; border: none; vertical-align: top;"><div style="margin: 0;"><span style="display: block; color: rgb(48,44,42); font-size: 20px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><strong style="display: inline-block; margin-right: 10px;">Caregiver Roundtable Discussion</strong><span style="display: inline-block; vertical-align: middle;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/inperson2.png" style="width: 16px; height: 18px; margin: 0 0 0 6px; vertical-align: middle;"/><span style="color: rgb(6,125,143); vertical-align: middle; font-size: 16px;"> In Person</span></span></span><span style="display: block; color: #666; font-size: 16px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> IgA Nephropathy Foundation • Wall, NJ </span><div style="margin-top: 12px;"><a href="https://www.facebook.com/955913750072294/posts/1006446131685722?utm_source=iga-nephropathy-insights&utm_content=in-person-event&utm_topic=social" rel="noopener noreferrer" style="display: inline-flex; align-items: center; padding: 8px 16px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; margin-right: 12px; transition: all 0.2s ease; border: 2px solid rgb(6,125,143);" target="_blank"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/info.png" style="width: 16px; height: 16px; margin-right: 6px;"/> More Info </a><a href="https://healthspotlight-newsletters.s3.amazonaws.com/calendar_events/caregiver_roundtable_discussion-iga_nephropathy_foundation-20250927.ics?utm_source=iga-nephropathy-insights&utm_content=in-person-event&utm_topic=social" style="display: inline-flex; align-items: center; padding: 8px 16px; border: 2px solid rgb(6,125,143); color: rgb(6,125,143); text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; transition: all 0.2s ease;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/calendar2.png" style="width: 16px; height: 16px; margin-right: 6px;"/> Add to Calendar </a></div></div></td></tr></table></td></tr></div></td></tr></table><tr><td style="padding: 15px 0;"></td></tr><tr><td style="padding: 0 0 20px 0;"><div style="text-align: center;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-right: -5px;"></div><a href="https://www.allmyhealth.io/our-communities/iga-nephropathy?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="display: inline-block; padding: 8px 16px; background-color: white; color: rgb(6,125,143); text-decoration: none; border-radius: 10px; font-family: Roboto, Arial, sans-serif; font-size: 14px; border: 1px solid rgb(6,125,143); margin: 0; font-weight: bold;" target="_blank"> Subscribe </a><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-left: -5px;"></div></div></td></tr></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=02ea3b12-4d5a-4b74-abeb-3dda2a80fe53&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>FDA Approves Atrasentan for IgA Nephropathy Proteinuria</description>
  <link>https://iga-nephropathy.beehiiv.com/p/09042025</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/09042025</guid>
  <pubDate>Wed, 09 Apr 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-04-09T18:00:00Z</atom:published>
    <category><![CDATA[Newsletter]]></category>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: #f6f4f2; overflow: hidden; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Top Stories</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.ajmc.com/view/fda-approves-atrasentan-for-proteinuria-reduction-in-primary-iga-nephropathy?utm_source=iga-nephropathy-insights&utm_content=news&utm_topic=pharmaceutical-insights" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgb(235,232,230); border-left: 4px solid rgb(6,125,143); transition: background 0.2s ease;"><div style="color: rgb(48,44,42); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">FDA Approves Atrasentan for IgA Nephropathy Proteinuria</div><div style="margin: 0; line-height: 1.6; color: #444; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">People with IgA Nephropathy now have a new treatment option, atrasentan, which reduces protein in the urine, a key factor in preventing kidney failure. It can be added to existing treatments without special safety monitoring.</div><span style="color: rgb(6,125,143); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a><a href="https://medicaldialogues.in/nephrology/news/fda-grants-accelerated-approval-to-atrasentan-for-iga-nephropathy-146017?utm_source=iga-nephropathy-insights&utm_content=news&utm_topic=pharmaceutical-insights" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgb(235,232,230); border-left: 4px solid rgb(6,125,143); transition: background 0.2s ease;"><div style="color: rgb(48,44,42); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">FDA Approves Atrasentan for IgA Nephropathy Treatment</div><div style="margin: 0; line-height: 1.6; color: #444; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">A new treatment option, atrasentan, can help reduce excess protein in the urine for people with IgA Nephropathy, potentially slowing kidney damage progression.</div><span style="color: rgb(6,125,143); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin-bottom: 0px 20px 20px 20px; padding: 20px;"><div style="margin: 0; line-height: 1.6; color: #444; text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Epigenetic modifications play a crucial role in understanding kidney diseases like IgA nephropathy. <a href="https://link.springer.com/article/10.1007/s10157-025-02668-x?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="color: rgb(6,125,143) !important; text-decoration: none;" target="_blank"><span style="color: rgb(6,125,143);"><strong>Sasaki and Masaki (2025)</strong></span></a> These modifications involve changes in gene expression without altering the DNA sequence itself, affecting how genes are turned on or off. This can influence disease progression and provide insights into how IgA nephropathy develops. <br/><br/> Research highlights the role of histone-modifying enzymes in inducing specific types of methylation, leading to changes in chromatin structure and gene expression. Studying these mechanisms could uncover new targets for treating kidney diseases, potentially leading to better management strategies for conditions like IgA nephropathy by exploring how epigenetic changes influence disease outcomes <a href="https://link.springer.com/article/10.2025/s20257-025-20258-x?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="color: rgb(6,125,143) !important; text-decoration: none;" target="_blank"><span style="color: rgb(6,125,143);"><strong>(Sasaki & Masaki, 2025)</strong></span></a>.</div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Clinical Trials</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin: 0 20px 25px; text-align: justify; color: rgb(48,44,42); font-size: 16px; line-height: 1.6;"> This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks: </div><div style="margin: 0 20px;"><a href="https://clinicaltrials.gov/study/NCT06740526?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-ii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,0.75); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase II</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">2 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">16+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">25</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06466135?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-ii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Study of WAL0921 in Patients With Glomerular Kidney Diseases </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,0.75); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase II</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">3 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18 - 75 Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">96</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT05797610?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">21 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">428</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT01802034?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=observational" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID) </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: white; color: #333; display: inline-block; font-size: 13px; font-weight: 500;">Observational</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">New York</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">2000</div></td></tr></table></div></a><div style="text-align: left; margin-top: 30px; margin-bottom: 20px;"><a href="https://clinicaltrials.gov/search?cond=IgA%20Nephropathy&aggFilters=status:rec&utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=all-trials" rel="noopener noreferrer" style="color: rgb(6,125,143); text-decoration: none; font-weight: bold; font-size: 15px;" target="_blank"> View the full list of clinical trials → </a></div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Community News</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.facebook.com/955913750072294/posts/1001663218830680?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=news-and-updates" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Apr 03, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">"Today's approval marks an important milestone for people living with IgA nephropathy, offering a new option that can be seamlessly integrated into their existing treatment plan, with no REMS requirement," said Richard Lafayette, M.D., F.A.C.P., Professor of Medicine, Nephrology and Director of the Glomerular Disease Center at Stanford University Medical Center, and Vanrafia ALIGN Study Investigator and Steering Committee Member. "Vanrafia is a selective ETA receptor antagonist that effectively reduces proteinuria, a major risk factor in IgAN. Taking early, decisive action is critical to help improve outcomes for these patients who too often progress toward kidney failure." source: <strong style="color: rgb(6,125,143);">Novartis.com</strong><br/><br/>Our future looks bright. You are not alone. ❤️💙 As soon as we receive patient facing materials we will update this post and share with our IgAN Community.<br/><br/>Learn More</p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="IgA Nephropathy Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250408-1" style="width: 100%; height: auto; display: block;"/></div></div></a><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Upcoming Events</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div></td></tr><tr><td><table style="width: 100%; max-width: 600px; margin-bottom: 28px; padding-top: 20px; border: none; border-collapse: separate; overflow: hidden;"><tr><td rowspan="1" style="width: 110px; text-align: center; vertical-align: top; padding: 0; border: none; padding-bottom: 40px;"><table style="width: 110px; border: 3px solid rgb(6,125,143); border-radius: 18px; background: #f6f4f2; border-collapse: separate; overflow: hidden;"><tr><td style="background: rgb(6,125,143); color: white; text-align: center; padding: 8px 0; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; border-radius: 15px 15px 0 0; font-size: 16px;"> APR </td></tr><tr><td style="text-align: center; padding: 8px 0; font-size: 36px; font-weight: bold; color: rgb(6,125,143); font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> 16 </td></tr></table></td><td style="padding: 0 0 40px 20px; border: none; vertical-align: top;"><div style="margin: 0;"><span style="display: block; color: rgb(48,44,42); font-size: 20px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><strong style="display: inline-block; margin-right: 10px;">Finding a Living Donor Webinar</strong><span style="display: inline-block; vertical-align: middle;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/online2.png" style="width: 16px; height: 18px; margin: 0 0 0 6px; vertical-align: middle;"/><span style="color: rgb(6,125,143); vertical-align: middle; font-size: 16px;">Online</span></span></span><span style="display: block; color: #666; font-size: 16px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> IgA Nephropathy Foundation • Wall, NJ </span><div style="margin-top: 12px;"><a href="https://www.facebook.com/955913750072294/posts/1002785812051754?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=educational" rel="noopener noreferrer" style="display: inline-flex; align-items: center; padding: 8px 16px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; margin-right: 12px; transition: all 0.2s ease; border: 2px solid rgb(6,125,143);" target="_blank"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/info.png" style="width: 16px; height: 16px; margin-right: 6px;"/> More Info </a><a href="https://healthspotlight-newsletters.s3.amazonaws.com/calendar_events/finding_a_living_donor_webinar-iga_nephropathy_foundation-20250416.ics?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=educational" style="display: inline-flex; align-items: center; padding: 8px 16px; border: 2px solid rgb(6,125,143); color: rgb(6,125,143); text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; transition: all 0.2s ease;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/calendar2.png" style="width: 16px; height: 16px; margin-right: 6px;"/> Add to Calendar </a></div></div></td></tr><tr><td rowspan="1" style="width: 110px; text-align: center; vertical-align: top; padding: 0; border: none; padding-bottom: 40px;"><table style="width: 110px; border: 3px solid rgb(6,125,143); border-radius: 18px; background: #f6f4f2; border-collapse: separate; overflow: hidden;"><tr><td style="background: rgb(6,125,143); color: white; text-align: center; padding: 8px 0; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; border-radius: 15px 15px 0 0; font-size: 16px;"> APR </td></tr><tr><td style="text-align: center; padding: 8px 0; font-size: 36px; font-weight: bold; color: rgb(6,125,143); font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> 30 </td></tr></table></td><td style="padding: 0 0 40px 20px; border: none; vertical-align: top;"><div style="margin: 0;"><span style="display: block; color: rgb(48,44,42); font-size: 20px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><strong style="display: inline-block; margin-right: 10px;">IgAN treatment option webinar</strong><span style="display: inline-block; vertical-align: middle;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/online2.png" style="width: 16px; height: 18px; margin: 0 0 0 6px; vertical-align: middle;"/><span style="color: rgb(6,125,143); vertical-align: middle; font-size: 16px;">Online</span></span></span><span style="display: block; color: #666; font-size: 16px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> IgA Nephropathy Foundation • Wall, NJ </span><div style="margin-top: 12px;"><a href="https://www.facebook.com/955913750072294/posts/1005776311752704?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=educational" rel="noopener noreferrer" style="display: inline-flex; align-items: center; padding: 8px 16px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; margin-right: 12px; transition: all 0.2s ease; border: 2px solid rgb(6,125,143);" target="_blank"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/info.png" style="width: 16px; height: 16px; margin-right: 6px;"/> More Info </a><a href="https://healthspotlight-newsletters.s3.amazonaws.com/calendar_events/igan_treatment_option_webinar-iga_nephropathy_foundation-20250430.ics?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=educational" style="display: inline-flex; align-items: center; padding: 8px 16px; border: 2px solid rgb(6,125,143); color: rgb(6,125,143); text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; transition: all 0.2s ease;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/calendar2.png" style="width: 16px; height: 16px; margin-right: 6px;"/> Add to Calendar </a></div></div></td></tr><tr><td rowspan="1" style="width: 110px; text-align: center; vertical-align: top; padding: 0; border: none; padding-bottom: 40px;"><table style="width: 110px; border: 3px solid rgb(6,125,143); border-radius: 18px; background: #f6f4f2; border-collapse: separate; overflow: hidden;"><tr><td style="background: rgb(6,125,143); color: white; text-align: center; padding: 8px 0; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; border-radius: 15px 15px 0 0; font-size: 16px;"> SEP </td></tr><tr><td style="text-align: center; padding: 8px 0; font-size: 36px; font-weight: bold; color: rgb(6,125,143); font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> 27 </td></tr></table></td><td style="padding: 0 0 40px 20px; border: none; vertical-align: top;"><div style="margin: 0;"><span style="display: block; color: rgb(48,44,42); font-size: 20px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><strong style="display: inline-block; margin-right: 10px;">Caregiver Roundtable Discussion</strong><span style="display: inline-block; vertical-align: middle;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/inperson2.png" style="width: 16px; height: 18px; margin: 0 0 0 6px; vertical-align: middle;"/><span style="color: rgb(6,125,143); vertical-align: middle; font-size: 16px;">In Person</span></span></span><span style="display: block; color: #666; font-size: 16px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> IgA Nephropathy Foundation • Wall, NJ </span><div style="margin-top: 12px;"><a href="https://www.facebook.com/955913750072294/posts/1006446131685722?utm_source=iga-nephropathy-insights&utm_content=in-person-event&utm_topic=social" rel="noopener noreferrer" style="display: inline-flex; align-items: center; padding: 8px 16px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; margin-right: 12px; transition: all 0.2s ease; border: 2px solid rgb(6,125,143);" target="_blank"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/info.png" style="width: 16px; height: 16px; margin-right: 6px;"/> More Info </a><a href="https://healthspotlight-newsletters.s3.amazonaws.com/calendar_events/caregiver_roundtable_discussion-iga_nephropathy_foundation-20250927.ics?utm_source=iga-nephropathy-insights&utm_content=in-person-event&utm_topic=social" style="display: inline-flex; align-items: center; padding: 8px 16px; border: 2px solid rgb(6,125,143); color: rgb(6,125,143); text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; transition: all 0.2s ease;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/calendar2.png" style="width: 16px; height: 16px; margin-right: 6px;"/> Add to Calendar </a></div></div></td></tr></table></td></tr></div></td></tr><tr><td style="padding: 30px 0;"></td></tr><tr><td style="padding: 0 0 20px 0;"><div style="text-align: center;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-right: -5px;"></div><a href="https://www.allmyhealth.io/work-with-us?utm_tag=community-waitlist&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="display: inline-block; padding: 8px 16px; background-color: white; color: rgb(6,125,143); text-decoration: none; border-radius: 10px; font-family: Roboto, Arial, sans-serif; font-size: 14px; border: 1px solid rgb(6,125,143); margin: 0; font-weight: bold;" target="_blank"> Advertise with us </a><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-left: -5px;"></div></div></td></tr></table></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=8e781a95-dd95-41c6-8a44-3167908362a5&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>This week&#39;s must-know community updates, latest research &amp; events</description>
  <link>https://iga-nephropathy.beehiiv.com/p/02042025</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/02042025</guid>
  <pubDate>Wed, 02 Apr 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-04-02T18:00:00Z</atom:published>
    <category><![CDATA[Newsletter]]></category>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: #f6f4f2; overflow: hidden; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><tr><td style="padding: 15px 0px;"><div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin-bottom: 0px 20px 20px 20px; padding: 20px;"><div style="margin: 0; line-height: 1.6; color: #444; text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">IgA nephropathy involves the deposition of IgA immune complexes in the kidneys, causing inflammation and potential damage. Symptoms include hematuria, proteinuria, and edema. The disease progresses slowly over years, leading to complications like high blood pressure and chronic kidney disease. <br/><br/> Treatment typically involves medications such as ACE inhibitors and ARBs to manage blood pressure and protein loss, along with corticosteroids to reduce inflammation. Lifestyle changes, including diet modifications and smoking cessation, are also recommended. While there is no cure, these interventions can help slow disease progression and prevent complications, as noted in ongoing research into new treatments <a href="https://pubmed.ncbi.nlm.nih.gov/40156299/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="color: rgb(6,125,143) !important; text-decoration: none;" target="_blank"><span style="color: rgb(6,125,143);"><strong>(Aubron et al., 2025)</strong></span></a>.</div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Clinical Trials</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin: 0 20px 25px; text-align: justify; color: rgb(48,44,42); font-size: 16px; line-height: 1.6;"> This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks: </div><div style="margin: 0 20px;"><a href="https://clinicaltrials.gov/study/NCT06209177?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-ii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,0.75); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase II</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">New Zealand</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18 - 70 Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">66</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06564142?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">26 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">480</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06291376?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">33 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">510</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06819826?utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=phase-iii" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">China</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">360</div></td></tr></table></div></a><div style="text-align: left; margin-top: 30px; margin-bottom: 20px;"><a href="https://clinicaltrials.gov/search?cond=IgA%20Nephropathy&aggFilters=status:rec&utm_source=iga-nephropathy-insights&utm_content=trials&utm_topic=all-trials" rel="noopener noreferrer" style="color: rgb(6,125,143); text-decoration: none; font-weight: bold; font-size: 15px;" target="_blank"> View the full list of clinical trials → </a></div></div></div><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Upcoming Events</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div></td></tr><tr><td><table style="width: 100%; max-width: 600px; margin-bottom: 28px; padding-top: 20px; border: none; border-collapse: separate; overflow: hidden;"><tr><td rowspan="1" style="width: 110px; text-align: center; vertical-align: top; padding: 0; border: none; padding-bottom: 40px;"><table style="width: 110px; border: 3px solid rgb(6,125,143); border-radius: 18px; background: #f6f4f2; border-collapse: separate; overflow: hidden;"><tr><td style="background: rgb(6,125,143); color: white; text-align: center; padding: 8px 0; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; border-radius: 15px 15px 0 0; font-size: 16px;"> SEP </td></tr><tr><td style="text-align: center; padding: 8px 0; font-size: 36px; font-weight: bold; color: rgb(6,125,143); font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> 10 </td></tr></table></td><td style="padding: 0 0 40px 20px; border: none; vertical-align: top;"><div style="margin: 0;"><span style="display: block; color: rgb(48,44,42); font-size: 20px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><strong style="display: inline-block; margin-right: 10px;">Advocacy event in Washington, D.C.</strong><span style="display: inline-block; vertical-align: middle;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/inperson2.png" style="width: 16px; height: 18px; margin: 0 0 0 6px; vertical-align: middle;"/><span style="color: rgb(6,125,143); vertical-align: middle; font-size: 16px;">In Person</span></span></span><span style="display: block; color: #666; font-size: 16px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> IgA Nephropathy Foundation • Wall, NJ </span><div style="margin-top: 12px;"><a href="https://www.facebook.com/955913750072294/posts/993878146275854?utm_source=iga-nephropathy-insights&utm_content=in-person-event&utm_topic=advocacy" rel="noopener noreferrer" style="display: inline-flex; align-items: center; padding: 8px 16px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; margin-right: 12px; transition: all 0.2s ease; border: 2px solid rgb(6,125,143);" target="_blank"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/info.png" style="width: 16px; height: 16px; margin-right: 6px;"/> More Info </a><a href="https://healthspotlight-newsletters.s3.amazonaws.com/calendar_events/advocacy_event_in_washington__d_c_-iga_nephropathy_foundation-20250910.ics?utm_source=iga-nephropathy-insights&utm_content=in-person-event&utm_topic=advocacy" style="display: inline-flex; align-items: center; padding: 8px 16px; border: 2px solid rgb(6,125,143); color: rgb(6,125,143); text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; transition: all 0.2s ease;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/calendar2.png" style="width: 16px; height: 16px; margin-right: 6px;"/> Add to Calendar </a></div></div></td></tr></table></td></tr></td></tr><tr><td style="padding: 30px 0;"></td></tr><tr><td style="padding: 0 0 20px 0;"><div style="text-align: center;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-right: -5px;"></div><a href="https://www.allmyhealth.io/work-with-us?utm_tag=community-waitlist&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="display: inline-block; padding: 8px 16px; background-color: white; color: rgb(6,125,143); text-decoration: none; border-radius: 10px; font-family: Roboto, Arial, sans-serif; font-size: 14px; border: 1px solid rgb(6,125,143); margin: 0; font-weight: bold;" target="_blank"> Advertise with us </a><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-left: -5px;"></div></div></td></tr></table></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=e7981dfd-5a47-4606-8fe9-d3101c6f8f46&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>This week&#39;s must-know community updates, latest research &amp; events</description>
  <link>https://iga-nephropathy.beehiiv.com/p/19032025</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/19032025</guid>
  <pubDate>Wed, 19 Mar 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-03-19T18:00:00Z</atom:published>
    <category><![CDATA[Newsletter]]></category>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: #f6f4f2; overflow: hidden; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><tr><td style="padding: 0;"><div style="background-color: rgb(235,232,230); padding: 30px; margin-top: 30px; margin-bottom: 30px; border-radius: 8px; box-shadow: 0 2px 5px rgba(0,0,0,0.1); font-family: Arial, sans-serif;"><a href="https://www.allmyhealth.io/reports/an-introduction-to-gene-therapy?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" style="text-decoration: none;" target="_blank"><h2 style="color: rgb(48,44,42); font-size: 24px; margin: 0; font-weight: 700; margin-bottom: 25px; line-height: 1.3; text-align: center;">Introduction to Gene Therapy - out now!</h2><table role="presentation" style="width: 100%;"><tr><td style="width: 60%; padding-right: 40px; vertical-align: top;"><p style="color: #555; font-size: 15px; margin: 10px 0; line-height: 1.5;">We're thrilled to announce the launch of the first guide in our gene & cell therapy series.</p><p style="color: #555; font-size: 15px; margin-top: 5px; margin-bottom: 2px; line-height: 1.5;">Read it for free here:</p><span style="color: rgb(6,125,143); font-size: 15px; text-decoration: none; font-weight: 500; display: inline-block;">www.allmyhealth.io/reports</span><p style="color: #555; font-size: 15px; margin-top: 18px; line-height: 1.6;">Stay tuned for next week when we will launch the next report in the series.</p><p style="color: #555; font-size: 15px; margin-top: 18px; line-height: 1.6;">Would you like to sponsor the next report in the series?</p></td><td style="width: 40%; vertical-align: top;"><img alt="Report Thumbnail" src="https://framerusercontent.com/images/LzCXPDC59DthtrU10XKfEgzHzw.png" style="width: auto; height: 260px; border-radius: 8px; box-shadow: 0 3px 10px rgba(0,0,0,0.15);"/></td></tr></table></a><a href="https://www.allmyhealth.io/sponsorship-opportunity?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" style="display: inline-block; background-color: rgb(6,125,143); color: white; text-decoration: none; padding: 12px 24px; border-radius: 6px; margin-top: 20px; font-weight: 600; font-size: 15px; transition: background-color 0.3s ease;">Enquire here</a></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Top Stories</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.healthcentral.com/condition/kidney-diseases/at-home-help-for-igan-swelling?utm_source=iga-nephropathy-insights&utm_content=news&utm_topic=patient-resources" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgb(235,232,230); border-left: 4px solid rgb(6,125,143); transition: background 0.2s ease;"><div style="color: rgb(48,44,42); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">At-Home Help for IgAN Swelling</div><div style="margin: 0; line-height: 1.6; color: #444; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Reducing swelling from IgAN involves lifestyle changes like elevating legs, exercising, and following a low-salt diet. These home strategies complement medical treatments to manage symptoms effectively.</div><span style="color: rgb(6,125,143); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin-bottom: 0px 20px 20px 20px; padding: 20px;"><div style="margin: 0; line-height: 1.6; color: #444; text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">In a study by <a href="https://www.tandfonline.com/doi/full/10.1080/0886022X.2025.2476052?utm_source=iga-nephropathy-insights&utm_content=research&utm_topic=diagnostic-insights&af=R" rel="noopener noreferrer" style="color: rgb(6,125,143) !important; text-decoration: none;" target="_blank"><span style="color: rgb(6,125,143);"><strong>Tu et al. (2025)</strong></span></a>, researchers developed a new way to grade the severity of intrarenal arterial lesions (IALs) in patients with IgA nephropathy (IgAN). They retrospectively analyzed patient data to see how these lesions affected the disease's progression. The team created a semi-quantitative scoring system to assess the IALs and applied it to a cohort of patients with IgAN. <br/><br/>They found that higher scores, indicating more severe IALs, were associated with a worse prognosis. This suggests that assessing the severity of IALs could be important for understanding how IgAN will progress in patients. The study's findings could help doctors better predict outcomes and tailor treatments for individuals with IgAN.</div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Clinical Trials</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin: 0 20px 25px; text-align: justify; color: rgb(48,44,42); font-size: 16px; line-height: 1.6;"> This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks: </div><div style="margin: 0 20px;"><a href="https://clinicaltrials.gov/study/NCT05834738?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,0.75); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase II</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">6 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">52</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06137768?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> A Trial of HRS-5965 Tablets in Primary IgA Nephropathy </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,0.75); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase II</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">China</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">115</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT06564142?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: rgba(6,125,143,1); color: white; display: inline-block; padding: 2px 8px; border-radius: 4px; width: fit-content; font-size: 12px; font-weight: 500">Phase III</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">25 countries</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">18+ Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">480</div></td></tr></table></div></a><a href="https://clinicaltrials.gov/study/NCT05190848?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="margin-bottom: 20px; background-color: white; border-radius: 8px; box-shadow: 0 2px 4px rgba(0,0,0,0.1); overflow: hidden; text-decoration: none; color: inherit; display: block;" target="_blank"><div style="padding: 12px 16px; border-bottom: 1px solid #f0f0f0;"><div style="display: flex; align-items: flex-start;"><div style="color: rgb(48,44,42); font-weight: bold; font-size: 16px; line-height: 1.4; flex: 1;"> Correlation of Microbiome and Metabonomics With IgA Nephropathy </div></div></div><div style="padding: 12px 16px;"><table style="width: 100%; border-collapse: collapse;"><tr><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Study Type</div><div style="background-color: white; color: #333; display: inline-block; font-size: 13px; font-weight: 500;">Observational</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Location</div><div style="font-size: 13px; color: #333; font-weight: 500;">China</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Age Range</div><div style="font-size: 13px; color: #333; font-weight: 500;">16 - 65 Years</div></td><td style="width: 25%; padding: 8px;"><div style="font-size: 12px; color: #777; margin-bottom: 4px;">Enrollment</div><div style="font-size: 13px; color: #333; font-weight: 500;">600</div></td></tr></table></div></a><div style="text-align: left; margin-top: 30px; margin-bottom: 20px;"><a href="https://clinicaltrials.gov/search?cond=IgA+Nephropathy&aggFilters=status%3Arec&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="color: rgb(6,125,143); text-decoration: none; font-weight: bold; font-size: 15px;" target="_blank"> View the full list of clinical trials → </a></div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Community News</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.facebook.com/955913750072294/posts/987003993629936?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=news-and-updates" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Mar 18, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">From a kitchen table in New Jersey to a global movement—what a journey it has been! The IgA Nephropathy Foundation was born out of necessity, fueled by a deep desire to support patients, drive research, and ensure that no one faces IgAN alone.<br/><br/>As we get ready to celebrate our 21st anniversary, I’m incredibly proud of how far we’ve come—from funding critical research and advocating on Capitol Hill to launching groundbreaking programs like IgAN Care and expanding our reach globally. But our work is far from over.<br/><br/>We invite you to read our latest feature in Seminars in Nephrology, where we reflect on our progress, the challenges ahead, and our unwavering commitment to finding a cure.<br/><br/>To every patient, caregiver, researcher, and supporter—this milestone is yours as much as it is ours. Thank you for being part of this journey. YOU ARE NOT ALONE ❤️ 💙<br/><br/>- Bonnie Schneider</p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="IgA Nephropathy Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250319-1" style="width: 100%; height: auto; display: block;"/></div></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><a href="https://www.facebook.com/955913750072294/posts/986210673709268?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=fundraising-and-events" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Mar 17, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">🚨 It’s Official – SPARK CHICAGO 2025 is SOLD OUT! 🚨<br/><br/>As of 10:00 AM ET, all spots for SPARK have been filled—for the 4th straight year! We are incredibly grateful for this IgAN community and the promise of hope that SPARK brings to all of us.<br/><br/>Missed your chance to register? Don’t worry—you can still join the waitlist, and we’ll do our best to get you in!<br/><br/>Thank you for your unwavering support. We can’t wait to make this year’s SPARK our most impactful yet! ❤️💙<br/><br/>130 days away ⏰️ 🗓️<br/><br/>Learn More <strong style="color: rgb(6,125,143);">iganspark.org</strong></p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="IgA Nephropathy Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250319-2" style="width: 100%; height: auto; display: block;"/></div></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><a href="https://www.facebook.com/955913750072294/posts/982953244035011?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=news-and-updates" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Mar 13, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">Join Us in Recognizing World Kidney Day!<br/><br/>Kidney health matters to all of us. While IgA Nephropathy is one type of kidney disease, chronic kidney disease (CKD) affects approximately 850 million people worldwide. If left undetected and untreated, CKD can lead to kidney failure, severe complications, and even premature mortality. By 2040, CKD is projected to become the 5th leading cause of years of life lost, underscoring the urgent need for global awareness and action.<br/><br/>This World Kidney Day, let’s come together to raise awareness, promote early detection, and advocate for better kidney health for all. Learn, share, and take action—because every kidney counts!</p></div></a><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Upcoming Events</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div></td></tr><tr><td><table style="width: 100%; max-width: 600px; margin-bottom: 28px; padding-top: 20px; border: none; border-collapse: separate; overflow: hidden;"><tr><td rowspan="1" style="width: 110px; text-align: center; vertical-align: top; padding: 0; border: none; padding-bottom: 40px;"><table style="width: 110px; border: 3px solid rgb(6,125,143); border-radius: 18px; background: #f6f4f2; border-collapse: separate; overflow: hidden;"><tr><td style="background: rgb(6,125,143); color: white; text-align: center; padding: 8px 0; font-weight: bold; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; border-radius: 15px 15px 0 0; font-size: 16px;"> APR </td></tr><tr><td style="text-align: center; padding: 8px 0; font-size: 36px; font-weight: bold; color: rgb(6,125,143); font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> 02 </td></tr></table></td><td style="padding: 0 0 40px 20px; border: none; vertical-align: top;"><div style="margin: 0;"><span style="display: block; color: rgb(48,44,42); font-size: 20px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><strong>IgA Nephropathy Diet Webinar</strong></span><span style="display: block; color: #666; font-size: 16px; margin-bottom: 8px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><span style="display: inline-flex; align-items: center;"> IgA Nephropathy Foundation • Wall, NJ    <img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/online2.png" style="width: 16px; height: 18px; margin: 0 6px; vertical-align: middle;"/><span style="color: rgb(6,125,143); vertical-align: middle;">Online</span></span></span><div style="margin-top: 12px;"><a href="https://www.facebook.com/955913750072294/posts/982163277447341?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=educational" rel="noopener noreferrer" style="display: inline-flex; align-items: center; padding: 8px 16px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; margin-right: 12px; transition: all 0.2s ease; border: 2px solid rgb(6,125,143);" target="_blank"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/info.png" style="width: 16px; height: 16px; margin-right: 6px;"/> More Info </a><a href="https://healthspotlight-newsletters.s3.amazonaws.com/calendar_events/iga_nephropathy_diet_webinar-iga_nephropathy_foundation-20250402.ics?utm_source=iga-nephropathy-insights&utm_content=online-event&utm_topic=educational" style="display: inline-flex; align-items: center; padding: 8px 16px; border: 2px solid rgb(6,125,143); color: rgb(6,125,143); text-decoration: none; border-radius: 20px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-size: 13px; transition: all 0.2s ease;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/calendar2.png" style="width: 16px; height: 16px; margin-right: 6px;"/> Add to Calendar </a></div></div></td></tr></table></td></tr></div></td></tr><tr><td style="padding: 30px 0;"></td></tr><tr><td style="padding: 0 0 20px 0;"><div style="text-align: center;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-right: -5px;"></div><a href="https://www.allmyhealth.io/work-with-us?utm_tag=community-waitlist&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="display: inline-block; padding: 8px 16px; background-color: white; color: rgb(6,125,143); text-decoration: none; border-radius: 10px; font-family: Roboto, Arial, sans-serif; font-size: 14px; border: 1px solid rgb(6,125,143); margin: 0; font-weight: bold;" target="_blank"> Advertise with us </a><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-left: -5px;"></div></div></td></tr></table></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=9e2adf9f-49d2-4790-98cc-a2a742665f58&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>Apply now: feature your voice in our cell and gene therapy series</description>
  <link>https://iga-nephropathy.beehiiv.com/p/06032025</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/06032025</guid>
  <pubDate>Fri, 07 Mar 2025 12:00:00 +0000</pubDate>
  <atom:published>2025-03-07T12:00:00Z</atom:published>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: #f6f4f2; overflow: hidden; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><tr><td style="padding: 15px 0px;"></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Don't miss out!</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin-bottom: 0px 20px 20px 20px; padding: 20px;"><div style="margin: 0; line-height: 1.6; color: #444; text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Thank you to everyone who has <a href="https://forms.gle/uLv39JF2Uf2B2B6D8?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="color: rgb(6,125,143) !important; text-decoration: none;" target="_blank"><span style="color: rgb(6,125,143);"><strong>completed our form </strong></span></a> and sent in questions they would like us to answer, and to those who would like to partner with us in sponsoring, contributing and distributing the cell and gene therapy guide. <br/><br/><strong>We would love to hear from more of you in this community and still have some partner slots left so please reach out asap by clicking below👇!</strong></div></div></div></td></tr><tr><td style="padding: 15px 0;"></td></tr><tr><td style="padding: 0px 0px 30px 0px;"><div style="border: 2px solid rgb(6,125,143); border-radius: 15px;"><div style="background-color: rgb(6,125,143); border-radius: 10px 10px 0px 0px; padding: 15px; text-align: center; color: white; font-size: 18px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-weight: bold;"> Apply now: feature your voice in our cell & gene therapy series </div><div style="background-color: #f6f4f2; padding: 20px; margin-top: 2px; border-radius: 15px; font-family: Arial, sans-serif; text-align: center; "><div style="color: rgb(48,44,42); font-size: 16px; line-height: 1.5; text-align: left; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> Cell and gene therapies are transforming rare disease treatment, offering new hope where options were once limited. But how do they work, and what choices exist for your community? </div><div style="margin-top: 10px; color: rgb(48,44,42); font-size: 16px; line-height: 1.5; text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> We're launching a special content series to help our 15k+ readers navigate this evolving landscape – and we need your voice! </div><div style="margin-top: 20px; font-size: 16px; color: rgb(48,44,42); text-align: left;"><strong>Be part of the conversation, whether you are: </strong></div><div style="margin: 15px 0 0 20px; padding: 0; color: rgb(48,44,42); font-size: 16px; text-align: left;"><div style="margin-top: 10px;">•   A patient or carer</div><div style="margin-top: 10px;">•   A patient support group</div><div style="margin-top: 10px;">•   Developing cell & gene therapies</div><div style="margin-top: 10px;">•   Administering cell & gene therapies</div></div></div><div style="margin-top: 20px; color: rgb(48,44,42); font-size: 16px; font-weight: bold; text-align: center;"> 📅 Enquiries close: March 12 </div><div style="margin-top: 20px; display: flex; justify-content: center;"><a href="https://forms.gle/AR33Wp1gVJAmo3xJ6?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" style="text-decoration: none;" target="_blank"><div style="background-color: rgb(6,125,143); color: white; padding: 15px 30px; border-radius: 5px; font-size: 16px; font-weight: bold; text-align: center;">Register your interest</div></a></div><div style="margin-top: 20px; font-weight: bold; font-size: 16px; color: rgb(48,44,42); text-align: center;"> Let's educate, advocate and drive change together. </div><div style="margin-bottom: 20px"></div></div></td></tr></table></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=b90bad8b-48e7-495c-9366-ea7bd7703210&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>This week&#39;s must-know community updates, latest research &amp; events</description>
  <link>https://iga-nephropathy.beehiiv.com/p/05032025</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/05032025</guid>
  <pubDate>Wed, 05 Mar 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-03-05T18:00:00Z</atom:published>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: #f6f4f2; overflow: hidden; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"><tr><td style="padding: 20px 0px;"><a href="https://www.linkedin.com/posts/all-my-health_allmyhealth-raredisease-patientempowerment-activity-7300930792346578945-qnEO?utm_source=share&utm_medium=member_desktop&rcm=ACoAADhVBJcBabaH_VWrKjIYLdVudX1BwpBcgPQ" style="text-decoration: none;" target="_blank"><div style="background-color: rgba(4, 17, 79, 0.06); padding: 15px; margin-top: 20px; border-radius: 10px; display: flex; align-items: center;"><div style="flex: 1;"><h4 style="color: rgb(48,44,42); font-size: 18px; margin: 0; font-weight:bold;">HealthSpotlight is now AllMyHealth!</h4><p style="color: #555; font-size: 14px; margin: 15px 0;">Read all about our exciting merger <strong>here</strong>.</p></div><div style="flex-shrink: 0; margin-left: 20px;"><img alt="Report Thumbnail" src="https://beehiiv-images-production.s3.amazonaws.com/uploads/asset/file/bfa3fd16-6a7e-4d41-926f-158e50d456dd/image.png?t=1741179443" style="width: 125px; height: auto; border-radius: 15px;"/></div></div></a></td></tr><tr><td style="padding: 0px 0px 30px 0px;"><div style="border: 2px solid rgb(6,125,143); border-radius: 15px;"><div style="background-color: rgb(6,125,143); border-radius: 10px 10px 0px 0px; padding: 15px; text-align: center; color: white; font-size: 18px; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important; font-weight: bold;"> Apply now: feature your voice in our cell & gene therapy series </div><div style="background-color: #f6f4f2; padding: 20px; margin-top: 2px; border-radius: 15px; font-family: Arial, sans-serif; text-align: center; "><div style="color: rgb(48,44,42); font-size: 16px; line-height: 1.5; text-align: left; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> Cell and gene therapies are transforming rare disease treatment, offering new hope where options were once limited. But how do they work, and what choices exist for your community? </div><div style="margin-top: 10px; color: rgb(48,44,42); font-size: 16px; line-height: 1.5; text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;"> We're launching a special content series to help our 15k+ readers navigate this evolving landscape – and we need your voice! </div><div style="margin-top: 20px; font-size: 16px; color: rgb(48,44,42); text-align: left;"><strong>Be part of the conversation, whether you are: </strong></div><div style="margin: 15px 0 0 20px; padding: 0; color: rgb(48,44,42); font-size: 16px; text-align: left;"><div style="margin-top: 10px;">•   A patient or carer</div><div style="margin-top: 10px;">•   A patient support group</div><div style="margin-top: 10px;">•   Developing cell & gene therapies</div><div style="margin-top: 10px;">•   Administering cell & gene therapies</div></div></div><div style="margin-top: 20px; color: rgb(48,44,42); font-size: 16px; font-weight: bold; text-align: center;"> 📅 Enquiries close: March 12 </div><div style="margin-top: 20px; display: flex; justify-content: center;"><a href="https://forms.gle/AR33Wp1gVJAmo3xJ6?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" style="text-decoration: none;" target="_blank"><div style="background-color: rgb(6,125,143); color: white; padding: 15px 30px; border-radius: 5px; font-size: 16px; font-weight: bold; text-align: center;">Register your interest</div></a></div><div style="margin-top: 20px; font-weight: bold; font-size: 16px; color: rgb(48,44,42); text-align: center;"> Let's educate, advocate and drive change together. </div><div style="margin-bottom: 20px"></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Top Stories</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.kidneyresearchuk.org/2025/03/04/disappointment-at-draft-nice-decision-to-reject-drug-for-rare-iga-nephropathy/?utm_source=iga-nephropathy-insights&utm_content=news&utm_topic=policy-and-regulation" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgb(235,232,230); border-left: 4px solid rgb(6,125,143); transition: background 0.2s ease;"><div style="color: rgb(48,44,42); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">NICE Draft Decision Rejects IgA Nephropathy Drug</div><div style="margin: 0; line-height: 1.6; color: #444; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Disappointment follows a draft decision to reject a drug for IgA Nephropathy, which could delay access to new treatments for patients with this condition. The decision affects those seeking additional treatment options to manage their condition.</div><span style="color: rgb(6,125,143); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a><a href="https://www.globenewswire.com/news-release/2025/02/26/3032907/0/en/Vera-Therapeutics-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html?utm_source=iga-nephropathy-insights&utm_content=news&utm_topic=pharmaceutical-insights" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgb(235,232,230); border-left: 4px solid rgb(6,125,143); transition: background 0.2s ease;"><div style="color: rgb(48,44,42); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">Vera Therapeutics Updates on Atacicept for IgA Nephropathy</div><div style="margin: 0; line-height: 1.6; color: #444; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Vera Therapeutics is advancing atacicept, a treatment aimed at slowing kidney damage in IgA Nephropathy patients. The company plans to announce key trial results and submit for FDA approval later this year.</div><span style="color: rgb(6,125,143); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a><a href="https://www.yourthurrock.com/2025/02/26/new-ramadan-guidance-for-kidney-patients/?utm_source=iga-nephropathy-insights&utm_content=news&utm_topic=patient-resources" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgb(235,232,230); border-left: 4px solid rgb(6,125,143); transition: background 0.2s ease;"><div style="color: rgb(48,44,42); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">New Ramadan Guidance for Kidney Patients</div><div style="margin: 0; line-height: 1.6; color: #444; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">Fasting during Ramadan poses health risks for those with IgA Nephropathy. This guidance helps patients understand these risks and make informed decisions about participating in fasting, emphasizing the importance of medical supervision.</div><span style="color: rgb(6,125,143); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><div style="margin-bottom: 0px 20px 20px 20px; padding: 20px;"><div style="margin: 0; line-height: 1.6; color: #444; text-align: justify; font-family: Inter, -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif !important;">In a study by <a href="https://link.springer.com/article/10.1007/s10157-025-02646-3?utm_source=iga-nephropathy-insights&utm_content=research&utm_topic=diagnostic-insights" rel="noopener noreferrer" style="color: rgb(6,125,143) !important; text-decoration: none;" target="_blank"><span style="color: rgb(6,125,143);"><strong>Fang (2025)</strong></span></a>, researchers used a method called Mendelian randomization to explore whether there's a genetic link between the number of white blood cells in the blood and the likelihood of developing IgA nephropathy. They found that certain white blood cells, specifically transitional B cells, might play a role in the development of this condition. This was determined by looking at genetic variations that are known to affect the levels of these cells and seeing if those same variations were more common in people with IgA nephropathy. <br/><br/>The findings suggest that having a higher count of these specific white blood cells could increase the risk of developing IgA nephropathy. This research could lead to better understanding of the disease and potentially to new ways to predict or prevent it. However, it's important to remember that this study looks at genetic predisposition and doesn't prove direct causation. Further research is needed to confirm these results and to explore the mechanisms involved.</div></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div><h2 style="color: rgb(6,125,143); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Community News</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><div><a href="https://www.facebook.com/955913750072294/videos/1299860104637259?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=fundraising-and-events" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Feb 28, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">📢 Today is Rare Disease Day – Show Your Stripes for IgAN!<br/><br/>No one fights IgAN alone. Today, we stand together to raise awareness for IgA Nephropathy and the millions affected by rare diseases worldwide.<br/><br/>Living with IgAN—or caring for someone who does—comes with challenges, but your story has the power to inspire and drive change. ❤️💙🦓<br/><br/>Join us in spreading awareness! Use our social media toolkit and share your story, post a photo, or use our graphics with <strong style="color: rgb(6,125,143);">#RareDiseaseDay</strong><strong style="color: rgb(6,125,143);">#ShowYourStripes</strong><strong style="color: rgb(6,125,143);">#IgAN</strong><br/><br/>Let’s make an impact—together.<br/><br/><strong style="color: rgb(6,125,143);">https://conta.cc/3Xp0lQt</strong></p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="IgA Nephropathy Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250305-1" style="width: 100%; height: auto; display: block;"/></div></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle;"></div></div><a href="https://www.facebook.com/955913750072294/posts/975260954804240?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=patient-resources" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: white; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(48,44,42); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Mar 03, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">Stress can be overwhelming. Take it one breath at a time.<br/><br/>________________________<br/><br/>Ever have one of those days when your to-do list is a mile long and you just don't know where to start? Stress can be helpful in moderation, but too much can leave you feeling dysregulated, anxious, and constantly on-edge.<br/><br/>If you're having one of these weeks—or just need some help taking a breather (literally)—here are three techniques to regulate your nervous system:<br/><br/>💙 Try a physiological sigh — two quick inhales through the nose then a long exhale through the mouth.<br/><br/>💙 Hum, sing or laugh — sounds silly but it can help to stimulate the parasympathetic nervous system.<br/><br/>💙 Put your feet on the ground — and if you're barefoot, even better. “Earthing” can rebalance your nervous system.<br/><br/>Reminder: All members receive a free Calm subscription to share with their family. Unlock your member benefit today.</p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="IgA Nephropathy Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250305-2" style="width: 100%; height: auto; display: block;"/></div></div></a></div></td></tr><tr><td style="padding: 30px 0;"></td></tr><tr><td style="padding: 40px 30px; background-color: rgba(6,125,143,0.1); border-radius: 10px; margin: 20px 0;"><div style="text-align: center;"><h2 style="color: rgb(6,125,143); font-size: 24px; margin-bottom: 15px;">Click Here to Join Our Community </h2><a href="mailto:info@allmyhealth.io" rel="noopener noreferrer" style="display: inline-block; padding: 12px 30px; background-color: rgb(6,125,143); color: white; text-decoration: none; border-radius: 25px; font-family: Roboto, Arial, sans-serif; font-size: 16px; font-weight: bold;" target="_blank"> Join Our Waitlist </a></div></td></tr><tr><td style="padding: 30px 0;"></td></tr><tr><td style="padding: 0 0 20px 0;"><div style="text-align: center;"><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-right: -5px;"></div><a href="https://www.allmyhealth.io/contact-us?utm_tag=community-waitlist&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="display: inline-block; padding: 8px 16px; background-color: white; color: rgb(6,125,143); text-decoration: none; border-radius: 10px; font-family: Roboto, Arial, sans-serif; font-size: 14px; border: 1px solid rgb(6,125,143); margin: 0; font-weight: bold;" target="_blank"> Advertise with us </a><div style="display: inline-block; width: 40px; height: 1px; background: rgb(6,125,143); vertical-align: middle; margin-left: -5px;"></div></div></td></tr></table></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=67259660-131a-4f3d-af59-630d4b227311&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>O. felineus Infection Impacts Kidney Function</description>
  <link>https://iga-nephropathy.beehiiv.com/p/19022025</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/19022025</guid>
  <pubDate>Wed, 19 Feb 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-02-19T18:00:00Z</atom:published>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: white; overflow: hidden; font-family: 'Roboto', sans-serif;"><tr><td style="padding: 0px 0px 40px 0px;"><a href="mailto:editorial@healthspotlight.io" rel="noopener noreferrer" target="_blank"><img alt="Advertise with us" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/advertise_banner.jpeg" style="width: 100%; max-width: 600px; height: auto; display: block; border: 0;"/></a></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div><h2 style="color: rgb(4,14,79); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Top Stories</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div></div><div><a href="https://www.docwirenews.com/post/o-felineus-infection-and-kidney-function?utm_source=iga-nephropathy-insights&utm_content=news&utm_topic=clinical-breakthroughs" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgba(4,14,79,0.03); border-left: 4px solid rgb(4,14,79); transition: background 0.2s ease;"><h3 style="color: rgb(4,14,79); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">O. felineus Infection Impacts Kidney Function</h3><p style="margin: 0; line-height: 1.6; color: #444;">Researchers found that infection with O. felineus, a liver fluke, is linked to kidney damage and IgA nephropathy. This connection suggests that people infected with O. felineus may need careful monitoring of their kidney health.</p><span style="color: rgb(4,14,79); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a><a href="https://www.docwirenews.com/post/long-term-outcomes-among-patients-with-igan-vary-widely?utm_source=iga-nephropathy-insights&utm_content=news&utm_topic=pharmaceutical-insights" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgba(4,14,79,0.03); border-left: 4px solid rgb(4,14,79); transition: background 0.2s ease;"><h3 style="color: rgb(4,14,79); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">Long-term outcomes in IgA Nephropathy vary widely</h3><p style="margin: 0; line-height: 1.6; color: #444;">Patients with IgA Nephropathy often face poor long-term outcomes, with many experiencing kidney failure. Persistent proteinuria is a significant risk factor for rapid kidney function decline.</p><span style="color: rgb(4,14,79); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div><h2 style="color: rgb(4,14,79); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div></div><div><div style="margin-bottom: 0px 20px 20px 20px; padding: 20px;"><p style="margin: 0; line-height: 1.6; color: #444; text-align: justify">In a case study by <a href="https://link.springer.com/article/10.1007/s40620-025-02213-9?utm_source=iga-nephropathy-insights&utm_content=research&utm_topic=diagnostic-insights" rel="noopener noreferrer" style="color: rgb(4, 14, 79); text-decoration: none;" target="_blank"><strong>Tomo (2025)</strong></a>, a patient with a history of alcoholic liver cirrhosis developed IgA nephropathy (IgAN), characterized by blood and protein in the urine. A kidney biopsy showed specific deposits in the kidney and mild cell proliferation. Tests indicated strong signals for immune proteins IgA and IgM in the kidney's filtering capillaries, with no distinction between two types of light chains, kappa and lambda. Electron microscopy confirmed the presence of these deposits in key areas of the kidney. The study also found that antibodies to a specific form of IgA that lacks galactose (a sugar molecule) were combined with regular IgA, and there was positive staining for proteins that inhibit cell death in macrophages along the kidney capillaries. These findings suggest that the mechanisms behind primary IgAN and IgAN related to alcoholism might be similar.</p></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div><h2 style="color: rgb(4,14,79); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Community News</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div></div><div><a href="https://www.facebook.com/955913750072294/posts/961705372826465?utm_source=iga-nephropathy-insights&utm_content=community" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: #ffffff; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(4,14,79); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Feb 14, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">PSA: Just in case you forgot, tomorrow is Valentine’s Day AND National Donor Day!<br/><br/>Don't worry, we’ve got you covered with some neph-tastically funny, shareable Valentine’s cards! 💕 Because nothing says love like a good kidney pun.<br/><br/>Tag your fellow IgAN warriors, kidney lovers, and rare disease rockstars—spread the love and the laughs! ❤️💙</p></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 60px; height: 1px; background: rgba(4,14,79,0.3);"></div></div><a href="https://www.facebook.com/955913750072294/posts/960883546241981?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=personal-stories" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: #ffffff; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(4,14,79); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Feb 12, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">Representation matters. We’re amplifying the voices of African American patients and caregivers in the IgAN community—because every experience brings us closer to a more informed and inclusive future. ❤️💙</p></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 60px; height: 1px; background: rgba(4,14,79,0.3);"></div></div><a href="https://www.facebook.com/955913750072294/posts/963978632599139?utm_source=iga-nephropathy-insights&utm_content=community&utm_topic=fundraising-and-events" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: #ffffff; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(4,14,79); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Feb 16, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">❤️💙 DON’T MISS OUT ON YOUR OPPORTUNITY TO CONNECT ⁠<br/><br/>We invite you to join our monthly virtual IgAN Support Groups! We hold these virtually on the third week of every month to give IgAN patients and care partners an opportunity to meet each other and share their journeys.⁠<br/><br/>⁠<br/><br/>⁠[Virtual] Patient Support Group⁠<br/><br/>Monday, February 17th 7PM ET⁠<br/><br/>⁠<br/><br/>⁠[Virtual] Caregiver|CarePartner Support Call⁠<br/><br/>Tuesday, February 18th 7PM ET⁠<br/><br/>⁠<br/><br/>⁠<br/><br/>Full schedule of upcoming support groups and other events at <strong style="color: rgb(4,14,79);">igan.org/events</strong></p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="IgA Nephropathy Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250219-1" style="width: 100%; height: auto; display: block;"/></div></div></a><tr><td><table style="width: 100%; max-width: 600px; margin-bottom: 28px; padding-top: 20px; border: none; border-collapse: separate; overflow: hidden;"></table></td></tr></div></td></tr><tr><td style="padding: 30px 0;"></td></tr><tr><td style="padding: 40px 30px; background-color: rgba(4,14,79,0.05); border-radius: 10px; margin: 20px 0;"><div style="text-align: center;"><h2 style="color: rgb(4,14,79); font-size: 24px; margin-bottom: 15px;">Click Here to Join Our Community </h2><a href="mailto:editorial@healthspotlight.io?utm_tag=community-list" rel="noopener noreferrer" style="display: inline-block; padding: 12px 30px; background-color: rgb(4,14,79); color: white; text-decoration: none; border-radius: 25px; font-family: Roboto, Arial, sans-serif; font-size: 16px; font-weight: bold;" target="_blank"> Join Our Waitlist </a></div></td></tr><tr><td style="padding: 30px 0;"></td></tr><tr><td style="padding: 0 0 20px 0;"><div style="text-align: center;"><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle; margin-right: -5px;"></div><a href="https://www.allmyhealth.io/contact-us?utm_tag=community-waitlist&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="display: inline-block; padding: 8px 16px; background-color: white; color: rgb(4,14,79); text-decoration: none; border-radius: 10px; font-family: Roboto, Arial, sans-serif; font-size: 14px; border: 1px solid rgba(4,14,79,0.3); margin: 0; font-weight: bold;" target="_blank"> Advertise with us </a><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle; margin-left: -5px;"></div></div></td></tr></table></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=765164f1-37fd-4ae4-b20a-f05193ea368e&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>Felzartamab Reduces Proteinuria in IgA Nephropathy</description>
  <link>https://iga-nephropathy.beehiiv.com/p/new-post</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/new-post</guid>
  <pubDate>Thu, 06 Feb 2025 16:00:00 +0000</pubDate>
  <atom:published>2025-02-06T16:00:00Z</atom:published>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table role="presentation" style="width: 100%; max-width: 600px; margin: 0 auto; background-color: white; overflow: hidden; font-family: 'Roboto', sans-serif;"><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div><h2 style="color: rgb(4,14,79); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Top Stories</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div></div><div><a href="https://medicaldialogues.in/nephrology/news/how-novel-antibody-felzartamab-impacts-iga-nephropathy-142140?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgba(4,14,79,0.03); border-left: 4px solid rgb(4,14,79); transition: background 0.2s ease;"><h3 style="color: rgb(4,14,79); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">Felzartamab Reduces Proteinuria in IgA Nephropathy</h3><p style="margin: 0; line-height: 1.6; color: #444;">Researchers found that felzartamab helps reduce proteinuria and maintain kidney function in people with IgA nephropathy, potentially allowing for less frequent treatment.</p><span style="color: rgb(4,14,79); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a><a href="https://www.wjtv.com/business/press-releases/cision/20250130CN06937/renalys-pharma-announces-completion-of-patient-enrollment-in-registrational-phase-iii-clinical-trial-of-sparsentan-for-iga-nephropathy-in-japan/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="text-decoration: none; color: inherit; display: block;" target="_blank"><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgba(4,14,79,0.03); border-left: 4px solid rgb(4,14,79); transition: background 0.2s ease;"><h3 style="color: rgb(4,14,79); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">Renalys Pharma Completes Enrollment for Sparsentan Trial in Japan</h3><p style="margin: 0; line-height: 1.6; color: #444;">Renalys Pharma has finished recruiting patients for a trial testing sparsentan, a medication aimed at slowing kidney function decline in people with IgA Nephropathy. The results could lead to its approval in Japan.</p><span style="color: rgb(4,14,79); display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;">Read More →</span></div></a></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div><h2 style="color: rgb(4,14,79); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div></div><div><div style="margin: 0px 20px 20px 20px; padding: 20px;"><p style="margin: 0; line-height: 1.6; color: #444; text-align: justify">In a study by <a href="https://www.researchsquare.com/article/rs-5904892/v1?utm_source=researcher_app&utm_medium=referral&utm_campaign=RESR_MRKT_Researcher_inbound" rel="noopener noreferrer" style="color: rgb(4, 14, 79); text-decoration: none;" target="_blank"><strong>Wang et al. (2025)</strong></a>, researchers found that higher levels of serum uric acid are significantly associated with more severe kidney damage in patients with IgA nephropathy. The study, which included 594 patients, revealed that those with elevated uric acid levels had lower kidney function, higher body mass index, blood pressure, and levels of certain blood components, as well as more severe protein leakage in the urine. These factors were used to create a predictive model, or nomogram, which showed moderate accuracy (C-index: 0.689) in forecasting the risk of disease progression to kidney failure or death. <br/><br/>The study also demonstrated that patients with high uric acid levels and severe kidney damage were at an increased risk of developing end-stage kidney disease or dying. This suggests that monitoring serum uric acid levels could be important for assessing the prognosis in IgA nephropathy patients. Wang et al. emphasize the potential of serum uric acid as an independent marker for kidney damage severity and long-term outcomes in these patients.</p></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div><h2 style="color: rgb(4,14,79); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Community News</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div></div><div><a href="https://www.facebook.com/955913750072294/posts/950636643933338?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: #ffffff; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(4,14,79); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Jan 29, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">Happy Lunar New Year - Welcoming the Year of the Snake<br/><br/>As we enter this new year, let's embrace the wisdom, flexibility, and growth the Snake represents. This is a time for renewal, strength, and thriving in the face of change.<br/><br/>Kelly Chen, a Nephrology Nurse Practitioner, IgAN patient, and member of our Medical & Scientific Advisory Board, shares how her family celebrates this special time:<br/><br/>"Lunar New Year is a time for family to come together and wish each other good fortune, prosperity, peace, health, and happiness. The foods we share carry deep meaning—dumplings symbolize wealth, nian gao (sticky rice cake) represents growth, fish sounds like abundance, and tang yuan (sweet rice balls) signify unity. I also love exchanging red envelopes to spread happiness and good fortune. This Year of the Snake will be extra special since I will be getting married!"<br/><br/>Wishing our IgAN community a year filled with abundance, unity, and new beginnings! ❤️💙 <strong style="color: rgb(4,14,79);">#YearOfTheSnake</strong><strong style="color: rgb(4,14,79);">#LunarNewYear</strong><strong style="color: rgb(4,14,79);">#IgANCommunity</strong></p></div></a><div style="text-align: center; margin: 0 auto 30px auto;"><div style="display: inline-block; width: 60px; height: 1px; background: rgba(4,14,79,0.3);"></div></div><a href="https://www.facebook.com/955913750072294/posts/954250516905284?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" rel="noopener noreferrer" style="text-decoration: none; color: inherit;" target="_blank"><div style="position: relative; margin-bottom: 30px; padding: 20px 20px 15px 20px; border-radius: 8px; background-color: #ffffff; border: 1px solid #ddd; box-shadow: 2px 2px 5px rgba(0,0,0,0.05);"><table style="width: 100%; margin-bottom: 15px;"><tr><td style="width: 50px;"><img alt="IgA Nephropathy Foundation" src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/page_icons/403148471557.png" style="width:50px; height:50px; border-radius:50%; border: 1px solid #ccc;"/></td><td style="padding-left: 10px;"><strong style="color: rgb(4,14,79); font-size:18px; display: block;">IgA Nephropathy Foundation</strong><span style="color: #999; font-size: 14px; display: block;">Feb 03, 2025</span></td><td style="width: 20px; text-align: right; vertical-align: top;"><img src="https://healthspotlight-newsletters.s3.us-east-1.amazonaws.com/assets/facebook.png" style="width: 20px; height: auto;"/></td></tr></table><p style="color: #333; margin: 0 0 10px 0;">If you can't have a good day, just have a day. That's good too.<br/><br/>Sometimes you just can't. Life feels colorless, there's nothing to look forward to, and getting out of bed feels pointless. Been there, done that, rotted in bed.<br/><br/>Even though we know we won't feel down forever, it doesn't make it easier. When you just can't with life, activate our "CAN'T" method.<br/><br/>❤️Comfort: Find comfort in something (a cup of tea or time in bed)<br/><br/>💙Action: Take a small action that might make you feel better (make your bed, meditate)<br/><br/>❤️Notice: How did that action make you feel? Any shifts in your mood?<br/><br/>💙Talk: Reach out to someone and tell them how you feel (isolating feels tempting but rarely helps)<br/><br/>We can't promise this will make you feel better, but it might distract you for a bit, which is a win.<br/><br/>Reminder: All members receive a free Calm subscription to share with their family.<br/><br/>Get Started Today<br/><br/><strong style="color: rgb(4,14,79);">https://www.calm.com/b2b/iga-nephropathy-foundation/subscribe</strong></p><div style="width: 100%; margin: 20px 0; border-radius: 5px;"><img alt="IgA Nephropathy Foundation Post" src="https://healthspotlight-newsletters.s3.amazonaws.com/post_images/01505377-41dc-4ba4-942e-8c36bf3f7081-20250205-1" style="width: 100%; height: auto; display: block;"/></div></div></a></div></td></tr></table></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=bc38ac69-d952-4bfd-bba7-b064a40908b7&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>IgA Nephropathy Insights</title>
  <description>Metabolic Syndrome Linked to Poor Outcomes in Kidney Disease Patients</description>
  <link>https://iga-nephropathy.beehiiv.com/p/iga-nephropathy-insights</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/iga-nephropathy-insights</guid>
  <pubDate>Thu, 23 Jan 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-01-23T18:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><div class="custom_html"><table style="width: 100%; background-color: white; overflow: hidden;"><tbody><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 30px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div><h2 style="color: rgb(4,14,79); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold;">Top Stories</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div></div><div><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgba(4,14,79,0.03); border-left: 4px solid rgb(4,14,79);"><h3 style="color: rgb(4,14,79); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">Metabolic Syndrome Linked to Poor Outcomes in Kidney Disease Patients</h3><p style="margin: 0; line-height: 1.6; color: #444;">A recent study found that components of metabolic syndrome, such as high blood pressure and cholesterol, are significantly linked to the prognosis of iga nephropathy. Managing these metabolic factors could improve outcomes for patients with iga nephropathy.</p><a href="https://medicaldialogues.in/nephrology/news/metabolic-syndrome-components-significantly-associated-with-prognosis-of-iga-nephropathy-finds-study-141804?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" style="color: rgb(4,14,79); text-decoration: none; display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;" rel="noopener noreferrer">Read More →</a></div><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgba(4,14,79,0.03); border-left: 4px solid rgb(4,14,79);"><h3 style="color: rgb(4,14,79); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">New Antibodies Linked to Prognosis in Kidney Diseases Like Lupus Nephritis</h3><p style="margin: 0; line-height: 1.6; color: #444;">Researchers have found that certain antibodies, such as anti-ETAR and anti-CXCR3, are associated with the prognosis of iga nephropathy and lupus nephritis, suggesting these markers could help predict disease outcomes. These findings could lead to better treatment strategies for patients with these conditions.</p><a href="https://www.hcplive.com/view/anti-etar-anti-cxcr3-antibodies-linked-iga-nephropathy-lupus-nephritis-prognosis?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" style="color: rgb(4,14,79); text-decoration: none; display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;" rel="noopener noreferrer">Read More →</a></div><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgba(4,14,79,0.03); border-left: 4px solid rgb(4,14,79);"><h3 style="color: rgb(4,14,79); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">New Study Reveals Incidence and Prevalence of IgA Nephropathy in the U.S.</h3><p style="margin: 0; line-height: 1.6; color: #444;">New research provides detailed insights into the incidence and prevalence of IgA nephropathy in the United States, helping to better understand the disease's impact on the population. The study highlights regional variations and demographic factors that influence the disease's occurrence.</p><a href="https://www.hcplive.com/view/new-research-provides-insight-into-incidence-prevalence-igan-united-states?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" style="color: rgb(4,14,79); text-decoration: none; display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;" rel="noopener noreferrer">Read More →</a></div><div style="margin-bottom: 20px; padding: 20px; border-radius: 8px; background: rgba(4,14,79,0.03); border-left: 4px solid rgb(4,14,79);"><h3 style="color: rgb(4,14,79); margin: 0 0 10px 0; font-size: 18px; font-weight: bold;">New Study: Urinary mRNA Could Be Key Biomarker for Kidney Disease Diagnosis</h3><p style="margin: 0; line-height: 1.6; color: #444;">Researchers are exploring the use of urinary sediment mRNA as a potential biomarker to diagnose and monitor IgA nephropathy, offering a non-invasive and more accurate way to track the disease. This approach could help in early detection and personalized treatment plans for patients with IgA nephropathy.</p><a href="https://docwirenews.com/post/urinary-sediment-mrna-as-a-biomarker-for-igan?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" style="color: rgb(4,14,79); text-decoration: none; display: inline-block; margin-top: 10px; font-size: 14px; font-weight: bold;" rel="noopener noreferrer">Read More →</a></div></div></td></tr><tr><td style="padding: 15px 0px;"><div style="text-align: center; margin-bottom: 10px;"><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div><h2 style="color: rgb(4,14,79); margin: 0 15px; display: inline-block; font-size: 26px; font-weight: bold; text-align: justify">Latest Research</h2><div style="display: inline-block; width: 40px; height: 1px; background: rgba(4,14,79,0.3); vertical-align: middle;"></div></div><div><div style="margin-bottom: 0px 20px 20px 20px; padding: 20px;"><p style="margin: 0; line-height: 1.6; color: #444; text-align: justify">Recent studies have provided new insights into IgA nephropathy. <a href="https://www.sciencedirect.com/science/article/pii/S1756464624006613?dgcid=rss_sd_all&utm_source=researcher_app&utm_medium=referral&utm_campaign=RESR_MRKT_Researcher_inbound" style="color: rgb(4, 14, 79);" rel="noopener noreferrer"><strong>Zhang et al. (2025)</strong></a> demonstrated that Cuscuta chinensis Lam. extract (CCLE) could be a promising therapeutic agent. Their research showed that CCLE improved kidney function in rats with IgA nephropathy by regulating specific signaling pathways. This suggests potential benefits for human treatment. <br><br> In another study, novel genetic locations associated with IgA nephropathy were identified, which could help understand its development and lead to new treatment strategies, as reported by <a href="https://www.news-medical.net/news/20250102/Study-identifies-novel-IgAN-loci-through-pleiotropy.aspx?utm_source=researcher_app&utm_medium=referral&utm_campaign=RESR_MRKT_Researcher_inbound" style="color: rgb(4, 14, 79);" rel="noopener noreferrer"><strong>Li et al. (2025)</strong></a>. <br><br> Lastly, <a href="https://www.nature.com/articles/s41598-025-85575-1?utm_source=researcher_app&utm_medium=referral&utm_campaign=RESR_MRKT_Researcher_inbound" style="color: rgb(4, 14, 79);" rel="noopener noreferrer"><strong>Lv et al. (2025)</strong></a> found that automated UF-5000 urinary erythrocyte parameters could effectively diagnose IgA nephropathy, potentially replacing traditional manual microscopy. This could streamline the diagnostic process and improve accuracy.</p></div></div></td></tr></tbody></table></div></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=ba97f40b-3cb7-4f8f-b91e-b3aa1195bf94&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>Weekly Spotlight - 09.01.25</title>
  <description>Alebund&#39;s New Funding Boosts Hope for Kidney Disease Treatments Globally</description>
  <link>https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-09-01-25</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-09-01-25</guid>
  <pubDate>Thu, 09 Jan 2025 18:00:00 +0000</pubDate>
  <atom:published>2025-01-09T18:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><p class="paragraph" style="text-align:center;"><a class="link" href="https://iga-nephropathy.healthspotlight.io/subscribe?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Subscribe</a> | Follow our <a class="link" href="https://www.linkedin.com/showcase/iga-nephropathy-insights/about/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">LinkedIn</a> page 🔗</p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:"Aptos Narrow", sans-serif;font-size:18pt;"><b>Community</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://forms.office.com/e/kEtaEqnVKA?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Share Your Story, Inspire Hope</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;">Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this <b><a class="link" href="https://forms.office.com/pages/responsepage.aspx?id=vUNT3cTym0-BeI37ZEWRG8EB4W-Y4JVJi5xFnmMx2iRUNURaVzZBS1NPMUFBVkw2VlE4RFJDODVPUS4u&route=shorturl&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">form</a></b> to be featured.</p></td></tr></table></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><h2 class="heading" style="text-align:center;"><b>Latest News</b></h2><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Falebund-pharmaceutical-announced-the-1st-closing-of-rmb-550-million-in-series-c-financing-302342508.html&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7C036c4b2a2b474d6a1ffe08dd30a7bd68%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638720219198611005%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=BU0Qr3gdF%2FVJlbE72msRgPeijEJ8SvTOWX7aUMw52zI%3D&reserved=0&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Alebund&#39;s New Funding Boosts Hope for Kidney Disease Treatments Globally</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">Alebund Pharmaceuticals secured $75 million in Series C funding, advancing renal disease therapies. Investors include a healthcare fund and Yangzhou Guojin Investment Group. The funds will aid in new drug applications, clinical studies, and commercial expansion in China, promising better options for kidney disease patients globally.</span></p><p class="paragraph" style="text-align:left;"><br></p><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41598-024-81929-3%3Futm_source%3Dresearcher_app%26utm_medium%3Dreferral%26utm_campaign%3DRESR_MRKT_Researcher_inbound&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7C036c4b2a2b474d6a1ffe08dd30a7bd68%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638720219198631370%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=3YCOIzglzAaAn9a3DW6pyY0%2F4t382S1pQOVgyaP5FcE%3D&reserved=0" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Metabolic Factors&#39; Critical Role in IgA Nephropathy Outcomes Explored</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">Metabolic syndrome affects IgA nephropathy prognosis. The study finds more metabolic components worsen renal survival, with blood pressure crucial in IgAN outcomes. Out of 698 patients, those with more symptoms faced poorer prognoses. Managing blood pressure is vital for improving outcomes in affected patients, offering hope in treatment strategies.</span></p><p class="paragraph" style="text-align:left;"><br></p><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.hcplive.com%2Fview%2Fnephrology-month-in-review-december-2024&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7C036c4b2a2b474d6a1ffe08dd30a7bd68%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638720219198649449%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=XDz4umBZjvS7aGMrSX%2FnUhrbi7cSb0TkEx3Bpky0nAs%3D&reserved=0&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Renal Breakthroughs Brighten Future for Kidney Disease Patients Globally</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">The December 2024 Nephrology Month review highlights significant advancements in kidney treatment. Key developments include the FDA&#39;s approval of a Phase 2 trial for ruxoprubart in IgAN and concerns over sotagliflozin for CKD. New research points to increased kidney replacement therapy risk in IgAN and FSGS patients.</span></p><p class="paragraph" style="text-align:left;"><br></p><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Facademic.oup.com%2Fintimm%2Farticle%2F37%2F2%2F75%2F7721690%3Frss%3D1%26utm_source%3Dresearcher_app%26utm_medium%3Dreferral%26utm_campaign%3DRESR_MRKT_Researcher_inbound&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7C036c4b2a2b474d6a1ffe08dd30a7bd68%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638720219198666053%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=hFv1tShyt%2BJsuhMJFpfgxtL892bF7mNXpUDOy5bStkA%3D&reserved=0" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Understanding IgA Nephropathy Opens New Chapter in Autoimmune Research</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">IgA Nephropathy is an autoimmune kidney disease where IgA antibodies target mesangial cells. Recent findings show certain bacteria may trigger this through molecular mimicry. This redefines the disease as tissue-specific, providing new hope for understanding its causes and developing specific treatments.</span></p></div><div class="image"><img alt="" class="image__image" style="border-radius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-sizing:border-box;border-color:#E5E7EB;" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9b6578ae-a61b-40f5-998f-8b9a29feccf5/Icon_Blue.png?t=1726247509"/></div><p class="paragraph" style="text-align:center;"><span style="font-size:0.6rem;">Health Spotlight’s IgA Nephropathy is a </span><span style="font-size:0.6rem;"><a class="link" href="https://www.contentive.com/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Contentive</a></span><span style="font-size:0.6rem;"> publication in the </span><span style="color:rgb(99, 32, 238);font-size:0.6rem;">Healthcare</span><span style="font-size:0.6rem;"> division</span></p></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=ec9771fb-d22a-4aab-8af1-0d2c6ebe8a1e&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>Weekly Spotlight - 19.12.24</title>
  <description>Innovative Treatments and Hopeful Advances in IgA Nephropathy Management</description>
  <link>https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-19-12-24</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-19-12-24</guid>
  <pubDate>Thu, 19 Dec 2024 18:00:00 +0000</pubDate>
  <atom:published>2024-12-19T18:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><p class="paragraph" style="text-align:center;"><a class="link" href="https://iga-nephropathy.healthspotlight.io/subscribe?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Subscribe</a> | Follow our <a class="link" href="https://www.linkedin.com/showcase/iga-nephropathy-insights/about/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">LinkedIn</a> page 🔗</p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:"Aptos Narrow", sans-serif;font-size:18pt;"><b>Community</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://forms.office.com/e/kEtaEqnVKA?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Share Your Story, Inspire Hope</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;">Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this <b><a class="link" href="https://forms.office.com/pages/responsepage.aspx?id=vUNT3cTym0-BeI37ZEWRG8EB4W-Y4JVJi5xFnmMx2iRUNURaVzZBS1NPMUFBVkw2VlE4RFJDODVPUS4u&route=shorturl&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">form</a></b> to be featured.</p></td></tr></table></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><h2 class="heading" style="text-align:center;"><b>Latest News</b></h2><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fjournals.lww.com%2Fpbj%2Ffulltext%2F2024%2F12000%2Femerging_perspectives_in_the_management_of_iga.1.aspx%3Futm_source%3Dresearcher_app%26utm_medium%3Dreferral%26utm_campaign%3DRESR_MRKT_Researcher_inbound&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7Cc56e5161286f44e0ed5208dd1f605768%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638701220840918237%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=sxlTaOk01yfm%2FzBLot6rVFnIxhb9E7P9JVIz%2B7xN85g%3D&reserved=0" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Innovative Treatments and Hopeful Advances in IgA Nephropathy Management</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">IgA nephropathy is a common kidney disease needing better treatments. Current therapies often fail, leading to costly kidney replacement. New research offers hope with innovative drugs and non-invasive tests. International trials are underway, aiming to improve patient outcomes and revise management guidelines. The future looks promising for IgAN care.</span></p><p class="paragraph" style="text-align:left;"><br></p><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Fnep.14419%3Faf%3DR%26sid%3Dresearcher%26utm_source%3Dresearcher_app%26utm_medium%3Dreferral%26utm_campaign%3DRESR_MRKT_Researcher_inbound%26sid%3Dresearcher&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7Cc56e5161286f44e0ed5208dd1f605768%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638701220840939925%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=jrCGoxcZAgkowbNWbpBEWV99IOhTfdLvFibddDktslA%3D&reserved=0" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Rare Medical Trio: Fabry Disease, IgA Nephropathy, and Crohn Coexistence</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">A 27-year-old woman with Crohn disease was diagnosed with both Fabry disease and IgA nephropathy. Her symptoms included haematuria and proteinuria. A kidney biopsy confirmed the conditions. This is the first known case of these three diseases coexisting, highlighting the need for thorough diagnostic evaluations.</span></p><p class="paragraph" style="text-align:left;"><br></p><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Facademic.oup.com%2Fckj%2Farticle%2Fdoi%2F10.1093%2Fckj%2Fsfae340%2F7890808%3Frss%3D1%26utm_source%3Dresearcher_app%26utm_medium%3Dreferral%26utm_campaign%3DRESR_MRKT_Researcher_inbound&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7Cc56e5161286f44e0ed5208dd1f605768%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638701220840956319%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=Lp4Vx8OntCFgh204PS0e6ZzJinDOnotSf9EFyBJN7GA%3D&reserved=0" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Non-invasive PET/CT Imaging Revolutionises IgA Nephropathy Monitoring and Care</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">This study explores a new, non-invasive method for assessing IgA nephropathy using PET/CT imaging. It shows promise in monitoring disease progression without the need for risky biopsies. The technique offers hope for patients, providing a safer way to track their condition and manage their health.</span></p><p class="paragraph" style="text-align:left;"><br></p><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdocwirenews.com%2Fpost%2Feffect-of-covid-19-infection-on-kidney-function-in-igan&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7Cc56e5161286f44e0ed5208dd1f605768%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638701220840972759%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=CYBnR3mzfGV6Hq5nz4AuiR8t69v1ave7J0PxN%2BP34nc%3D&reserved=0&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">COVID-19 Impact on Kidney Health in IgA Nephropathy Patients</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">The study by Miao Hui and colleagues found that mild to moderate COVID-19 does not significantly worsen kidney function in IgA nephropathy patients. Most had mild symptoms, and kidney function remained stable. This offers reassurance to patients, especially those with good baseline kidney health.</span></p></div><div class="image"><img alt="" class="image__image" style="border-radius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-sizing:border-box;border-color:#E5E7EB;" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9b6578ae-a61b-40f5-998f-8b9a29feccf5/Icon_Blue.png?t=1726247509"/></div><p class="paragraph" style="text-align:center;"><span style="font-size:0.6rem;">Health Spotlight’s IgA Nephropathy is a </span><span style="font-size:0.6rem;"><a class="link" href="https://www.contentive.com/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Contentive</a></span><span style="font-size:0.6rem;"> publication in the </span><span style="color:rgb(99, 32, 238);font-size:0.6rem;">Healthcare</span><span style="font-size:0.6rem;"> division</span></p></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=f31069ab-a086-4116-8483-ae47606511d2&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>Weekly Spotlight - 12.12.24</title>
  <description>Bisphosphonates and Cinacalcet: A Hopeful Solution for Post-Transplant Challenges</description>
  <link>https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-12-12-24</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-12-12-24</guid>
  <pubDate>Thu, 12 Dec 2024 18:00:00 +0000</pubDate>
  <atom:published>2024-12-12T18:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><p class="paragraph" style="text-align:center;"><a class="link" href="https://iga-nephropathy.healthspotlight.io/subscribe?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Subscribe</a> | Follow our <a class="link" href="https://www.linkedin.com/showcase/iga-nephropathy-insights/about/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">LinkedIn</a> page 🔗</p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:"Aptos Narrow", sans-serif;font-size:18pt;"><b>Community</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://forms.office.com/e/kEtaEqnVKA?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Share Your Story, Inspire Hope</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;">Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this <b><a class="link" href="https://forms.office.com/pages/responsepage.aspx?id=vUNT3cTym0-BeI37ZEWRG8EB4W-Y4JVJi5xFnmMx2iRUNURaVzZBS1NPMUFBVkw2VlE4RFJDODVPUS4u&route=shorturl&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">form</a></b> to be featured.</p></td></tr></table></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><h2 class="heading" style="text-align:center;"><b>Latest News</b></h2><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fonlinelibrary.wiley.com%2Fdoi%2F10.1111%2Fnep.14415%3Faf%3DR%26sid%3Dresearcher%26utm_source%3Dresearcher_app%26utm_medium%3Dreferral%26utm_campaign%3DRESR_MRKT_Researcher_inbound%26sid%3Dresearcher&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7Cf7c1d6dd619049f0d6c508dd1a9f707a%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638695994264818700%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=%2FlAkEHb6Ra9e5Xfu%2BRrLvrkcz6FcwdSpIaVLZwHNCOM%3D&reserved=0" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Bisphosphonates and Cinacalcet: A Hopeful Solution for Post-Transplant Challenges</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">Bisphosphonate therapy, combined with cinacalcet, shows promise in managing post-transplant hyperparathyroidism, a common issue in kidney transplant recipients. This approach helped improve renal function and reduce complications in a patient, offering hope for better outcomes. Total parathyroidectomy further stabilised the condition, maintaining kidney health.</span></p><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Facademic.oup.com%2Fglycob%2Farticle%2Fdoi%2F10.1093%2Fglycob%2Fcwae060%2F7726403%3Frss%3D1%26utm_source%3Dresearcher_app%26utm_medium%3Dreferral%26utm_campaign%3DRESR_MRKT_Researcher_inbound&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7Cf7c1d6dd619049f0d6c508dd1a9f707a%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638695994264864299%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=FNBzNg2eTDrErhErGU603pMBq1FtT5MSFlQ8%2BFMJf5E%3D&reserved=0" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Understanding IgA Nephropathy: Pathways to New Treatments</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">IgA nephropathy involves kidney damage from immune complexes with abnormally glycosylated IgA1. These complexes, bound by IgG autoantibodies, harm the kidneys, often leading to failure. Understanding these mechanisms is crucial for developing targeted treatments, as most patients face recurrent disease post-transplantation.</span></p><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Facademic.oup.com%2Fckj%2Farticle%2Fdoi%2F10.1093%2Fckj%2Fsfae327%2F7912575%3Frss%3D1%26utm_source%3Dresearcher_app%26utm_medium%3Dreferral%26utm_campaign%3DRESR_MRKT_Researcher_inbound&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7Cf7c1d6dd619049f0d6c508dd1a9f707a%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638695994264897561%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=GcjA3OSjMaWWlS7bdl14Y%2B6FUXgCMTNSizboeWPXnqs%3D&reserved=0" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Understanding Kidney Complications from Cancer Drugs: Insights and Hope</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">The SUBARU-J study examined kidney complications from anticancer drugs in Japan. It found lung cancer was most common, with tubulointerstitial nephritis and thrombotic microangiopathy frequent. Proton pump inhibitors worsened outcomes. Clinicians should note these findings to improve patient care and manage risks effectively.</span></p><h3 class="heading" style="text-align:left;"><span style="color:rgb(61, 128, 245);font-family:Roboto, -apple-system, BlinkMacSystemFont, Tahoma, sans-serif;font-size:16px;"><b><a class="link" href="https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.frontiersin.org%2Fjournals%2Fimmunology%2Farticles%2F10.3389%2Ffimmu.2024.1430356%2Ffull%3Futm_source%3Dresearcher_app%26utm_medium%3Dreferral%26utm_campaign%3DRESR_MRKT_Researcher_inbound&data=05%7C02%7Cliam.ball%40blenheimchalcot.com%7Cf7c1d6dd619049f0d6c508dd1a9f707a%7Cdd5343bdf2c44f9b81788dfb6445911b%7C0%7C0%7C638695994264929748%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=K%2BBQ4HzXrTsQjSltQnSh2XwnXc%2BrNeGUo7sV0XaEjEI%3D&reserved=0" target="_blank" rel="noopener noreferrer nofollow" style="color: rgb(61, 128, 245)">Exploring Nephrotic Syndrome: Gut Microbiota and Traditional Chinese Medicine Role</a></b></span></h3><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:"Aptos Narrow", sans-serif;font-size:16px;">Nephrotic syndrome severity is linked to gut microbiota changes. Traditional Chinese medicine (TCM) offers hope by regulating gut health, reducing inflammation, and stabilising the intestinal barrier. This approach may improve outcomes for patients, highlighting the potential of TCM in managing this challenging kidney condition.</span></p></div><div class="image"><img alt="" class="image__image" style="border-radius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-sizing:border-box;border-color:#E5E7EB;" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9b6578ae-a61b-40f5-998f-8b9a29feccf5/Icon_Blue.png?t=1726247509"/></div><p class="paragraph" style="text-align:center;"><span style="font-size:0.6rem;">Health Spotlight’s IgA Nephropathy is a </span><span style="font-size:0.6rem;"><a class="link" href="https://www.contentive.com/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Contentive</a></span><span style="font-size:0.6rem;"> publication in the </span><span style="color:rgb(99, 32, 238);font-size:0.6rem;">Healthcare</span><span style="font-size:0.6rem;"> division</span></p></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=93027095-b4f2-4099-9bfe-97bb023e589d&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>Weekly Spotlight - 27.11.24</title>
  <description>South Korea Approves Nefecon for Primary IgA Nephropathy Treatment</description>
  <link>https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-27-11-24</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-27-11-24</guid>
  <pubDate>Wed, 27 Nov 2024 18:00:00 +0000</pubDate>
  <atom:published>2024-11-27T18:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><p class="paragraph" style="text-align:center;"><a class="link" href="https://iga-nephropathy.healthspotlight.io/subscribe?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Subscribe</a> | Follow our <a class="link" href="https://www.linkedin.com/showcase/iga-nephropathy-insights/about/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">LinkedIn</a> page 🔗</p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Community</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://forms.office.com/e/kEtaEqnVKA?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">We want to hear your story!</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!</span></p></td></tr></table></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(5, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Latest News</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(60, 128, 245);font-family:Aptos Display, sans-serif;"><b><a class="link" href="https://www.biospectrumasia.com/news/51/25234/south-korea-approves-everest-medicines-nefecon-for-treatment-of-primary-iga-nephropathy.html?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">South Korea Approves Nefecon for Primary IgA Nephropathy Treatment</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="font-family:Aptos Narrow, sans-serif;font-size:12pt;">South Korea has approved Nefecon, a drug developed by Everest Medicines, for the treatment of primary iga nephropathy. This approval marks a significant advancement in managing the condition, offering a new therapeutic option to patients suffering from iga nephropathy. The drug aims to reduce proteinuria and slow disease progression.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(60, 128, 245);font-family:Aptos Display, sans-serif;"><b><a class="link" href="https://www.msn.com/en-us/health/other/novel-gene-therapy-ps-002-targets-podocytes-in-iga-nephropathy/ar-AA1t1NFx?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">New Gene Therapy Targets Kidney Cells in Rare Disease Treatment</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="font-family:Aptos Narrow, sans-serif;font-size:12pt;">Researchers are developing a new gene therapy, PS-002, to target podocytes in the kidneys of people with iga nephropathy. This therapy aims to protect these crucial cells and potentially slow or halt the progression of the disease. Early trials show promising results in improving kidney function.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(60, 128, 245);font-family:Aptos Display, sans-serif;"><b><a class="link" href="https://docwirenews.com/post/association-between-inflammatory-skin-diseases-and-iga-nephropathy?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Link Between Inflammatory Skin Conditions and Kidney Disease Identified in New Study</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="font-family:Aptos Narrow, sans-serif;font-size:12pt;">Research suggests a link between inflammatory skin diseases, such as psoriasis and atopic dermatitis, and an increased risk of developing iga nephropathy. The study highlights that patients with these skin conditions may need closer monitoring for kidney health. This connection could help in early detection and management of iga nephropathy.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(60, 128, 245);font-family:Aptos Display, sans-serif;"><b><a class="link" href="https://www.hcplive.com/view/impact-of-igan-on-quality-of-life?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">How IgA Nephropathy Affects Patients&#39; Quality of Life and Well-being</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="font-family:Aptos Narrow, sans-serif;font-size:12pt;">Living with iga nephropathy can significantly impact quality of life, affecting physical health, mental well-being, and social interactions. Symptoms like fatigue, pain, and frequent hospital visits can limit daily activities and emotional stability, highlighting the need for comprehensive care and support to manage the condition effectively.</span></p></td></tr></table></div></div><div class="image"><img alt="" class="image__image" style="border-radius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-sizing:border-box;border-color:#E5E7EB;" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9b6578ae-a61b-40f5-998f-8b9a29feccf5/Icon_Blue.png?t=1726247509"/></div><p class="paragraph" style="text-align:center;"><span style="font-size:0.6rem;">Health Spotlight’s IgA Nephropathy is a </span><span style="font-size:0.6rem;"><a class="link" href="https://www.contentive.com/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Contentive</a></span><span style="font-size:0.6rem;"> publication in the </span><span style="color:rgb(99, 32, 238);font-size:0.6rem;">Healthcare</span><span style="font-size:0.6rem;"> division</span></p></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=55896641-6b79-41e7-b27b-3b180b243f9b&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>Weekly Spotlight - 21.11.24</title>
  <description>Full Approval for New IgAN Treatments</description>
  <link>https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-21-11-24</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-21-11-24</guid>
  <pubDate>Thu, 21 Nov 2024 18:00:00 +0000</pubDate>
  <atom:published>2024-11-21T18:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><p class="paragraph" style="text-align:center;"><a class="link" href="https://iga-nephropathy.healthspotlight.io/subscribe?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Subscribe</a> | <a class="link" href="{{rp_referral_hub_url}}" target="_blank" rel="noopener noreferrer nofollow">Share with your community</a></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Community</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://forms.office.com/e/kEtaEqnVKA?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">We want to hear your story!</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!</span></p></td></tr></table></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(5, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Latest News</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(60, 128, 245);font-family:Aptos Display, sans-serif;"><b><a class="link" href="https://www.gov.uk/government/news/sparsentan-approved-to-treat-adult-patients-with-primary-immunoglobulin-a-nephropathy-igan?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">New Medication Approved for Adults with Primary Immunoglobulin A Nephropathy</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="font-family:Aptos Narrow, sans-serif;font-size:12pt;">The UK has approved a new drug called sparsentan to treat adult patients with IgA nephropathy, a kidney disease. This medication aims to slow down the progression of the disease and reduce proteinuria, a common symptom of IgA nephropathy. It offers a new treatment option for those affected by this condition.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(60, 128, 245);font-family:Aptos Display, sans-serif;"><b><a class="link" href="https://www.manilatimes.net/2024/11/19/tmt-newswire/pr-newswire/everest-medicines-announces-nefecon-has-received-full-approval-from-south-koreas-ministry-of-food-and-drug-safety-mfds-for-the-treatment-of-primary-iga-nephropathy/2006887?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Everest Medicines&#39; Nefecon Gains Full Approval in South Korea for Treating Primary IgA Nephropathy</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="font-family:Aptos Narrow, sans-serif;font-size:12pt;">Everest Medicines announced that Nefecon, a new medication, has been fully approved by South Korea&#39;s Ministry of Food and Drug Safety for the treatment of primary iga nephropathy, offering a new therapeutic option for patients with this condition.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(60, 128, 245);font-family:Aptos Display, sans-serif;"><b><a class="link" href="https://www.thepharmaletter.com/mhra-approves-filspari-for-igan?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">UK&#39;s MHRA Approves Filspari for Rare Kidney Disease Treatment</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="font-family:Aptos Narrow, sans-serif;font-size:12pt;">The UK&#39;s MHRA has approved Filspari, a new treatment for IgA nephropathy, a kidney disease. Filspari is designed to reduce proteinuria and slow the progression of the disease. This approval offers a new therapeutic option for patients suffering from IgA nephropathy, potentially improving their quality of life.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(60, 128, 245);font-family:Aptos Display, sans-serif;"><b><a class="link" href="https://www.renalandurologynews.com/indepth/an-update-on-novel-and-investigational-iga-nephropathy-treatments/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">New Treatments on the Horizon for IGA Nephropathy Patients</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="font-family:Aptos Narrow, sans-serif;font-size:12pt;">The article discusses new and experimental treatments for iga nephropathy, a kidney disease. It highlights various therapies, including medications and lifestyle changes, that are being researched to improve outcomes for patients with this condition. The focus is on potential future treatments that could offer better management and prevention of kidney damage.</span></p></td></tr></table></div></div><div class="image"><img alt="" class="image__image" style="border-radius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-sizing:border-box;border-color:#E5E7EB;" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9b6578ae-a61b-40f5-998f-8b9a29feccf5/Icon_Blue.png?t=1726247509"/></div><p class="paragraph" style="text-align:center;"><span style="font-size:0.6rem;">Health Spotlight’s IgA Nephropathy is a </span><span style="font-size:0.6rem;"><a class="link" href="https://www.contentive.com/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Contentive</a></span><span style="font-size:0.6rem;"> publication in the </span><span style="color:rgb(99, 32, 238);font-size:0.6rem;">Healthcare</span><span style="font-size:0.6rem;"> division</span></p></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=67e2d6e6-49af-4d65-8208-bbc8e183f70f&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>Weekly Spotlight - 14.11.24</title>
  <description>Critical advancements in IgAN treatments and understanding of risk factors.</description>
  <link>https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-14-11-24</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-14-11-24</guid>
  <pubDate>Thu, 14 Nov 2024 18:00:00 +0000</pubDate>
  <atom:published>2024-11-14T18:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><p class="paragraph" style="text-align:center;"><a class="link" href="https://iga-nephropathy.healthspotlight.io/subscribe?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Subscribe</a> | <a class="link" href="{{rp_referral_hub_url}}" target="_blank" rel="noopener noreferrer nofollow">Share with your community</a> | <a class="link" href="https://www.linkedin.com/showcase/iga-nephropathy/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Follow our LinkedIn page</a></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Community</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://forms.office.com/e/kEtaEqnVKA?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">We want to hear your story!</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!</span></p></td></tr></table></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>In the News</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.healthline.com/health-news/cardiovascular-kidney-metabolic-syndrome-heart-disease-risk?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Diabetes and Kidney Disease Significantly Elevate Cardiovascular Risk</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">New research highlights that individuals with both type 2 diabetes and chronic kidney disease face a significantly increased risk of cardiovascular disease, potentially 28 years earlier than those without these conditions. Experts recommend a heart-healthy lifestyle, including diet and exercise, to mitigate these risks.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://docwirenews.com/post/sc0062-effective-and-safe-in-patients-with-iga-nephropathy?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">SC0062 Shows Promise for IgA Nephropathy Treatment</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">The 2-SUCCEED trial explored SC0062, a new treatment for IgA nephropathy, showing promising results. SC0062 significantly reduced proteinuria without causing peripheral oedema, offering hope for patients. The trial involved 131 participants and demonstrated a favourable safety profile, suggesting SC0062 as an effective option for managing this condition.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.hcplive.com/view/igan-progression?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">IgA Nephropathy: Understanding Progression and Key Risk Factors</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">IgA nephropathy (IgAN) is a condition where IgA deposits in the kidneys, leading to progressive damage. Key factors like persistent proteinuria, hypertension, and reduced GFR can accelerate progression to end-stage renal disease (ESRD). Understanding these factors is crucial for managing and potentially slowing IgAN progression.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.sciencedirect.com/science/article/pii/S0891584924010219?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">SBP1&#39;s Role in IgA Nephropathy: A New Understanding</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">SBP1 plays a crucial role in IgA nephropathy by promoting mesangial cell proliferation and inflammation through mitochondrial respiration. Elevated SBP1 levels correlate with kidney damage, suggesting its potential as a therapeutic target. This discovery offers hope for better management of IgA nephropathy, improving patient outcomes.</span></p></td></tr></table></div></div><div class="image"><img alt="" class="image__image" style="border-radius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-sizing:border-box;border-color:#E5E7EB;" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9b6578ae-a61b-40f5-998f-8b9a29feccf5/Icon_Blue.png?t=1726247509"/></div><p class="paragraph" style="text-align:center;"><span style="font-size:0.6rem;">Health Spotlight’s IgA Nephropathy is a </span><span style="font-size:0.6rem;"><a class="link" href="https://www.contentive.com/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Contentive</a></span><span style="font-size:0.6rem;"> publication in the </span><span style="color:rgb(99, 32, 238);font-size:0.6rem;">Healthcare</span><span style="font-size:0.6rem;"> division</span></p></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=188b953d-ab48-4a9c-93f6-911400b81f7f&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>Weekly Spotlight - 07.11.24</title>
  <description>Breakthroughs, management options, and the impact of kidney disease on reproductive health</description>
  <link>https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-07-11-24</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-07-11-24</guid>
  <pubDate>Thu, 07 Nov 2024 18:00:00 +0000</pubDate>
  <atom:published>2024-11-07T18:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><p class="paragraph" style="text-align:center;"><a class="link" href="https://iga-nephropathy.healthspotlight.io/subscribe?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Subscribe</a> | <a class="link" href="{{rp_referral_hub_url}}" target="_blank" rel="noopener noreferrer nofollow">Share with your community</a></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Community</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://forms.office.com/e/kEtaEqnVKA?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">We want to hear your story!</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!</span></p></td></tr></table></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>In the News</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.sciencedirect.com/science/article/pii/S0891584924010219?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">SBP1 Elevates Mesangial Proliferation in IgA Nephropathy</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">SBP1 plays a crucial role in IgA nephropathy by promoting mesangial cell proliferation and inflammation through mitochondrial respiration. Elevated SBP1 levels correlate with kidney damage, suggesting its potential as a therapeutic target. This discovery offers hope for better management of IgA nephropathy, improving patient outcomes.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.tandfonline.com/doi/full/10.1080/0886022X.2024.2411846?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Predictive Value of Oxford Classification in Paediatric IgA Nephropathy</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">The Oxford Classification has been shown to be a significant tool for predicting the prognosis of children with IgA nephropathy. This systematic review and meta-analysis found that specific lesions, such as M, S, T, and C, are associated with poorer kidney outcomes. While the classification is widely used in adults, this research emphasizes its applicability and predictive value in pediatric cases, offering new insights into disease management for younger patients.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.news-medical.net/news/20241026/New-trial-shows-felzartamab-reduces-proteinuria-in-IgA-nephropathy-patients.aspx#:~:text=IgA%20nephropathy%20(IgAN)%20is%20an,and%20maintain%20patients&#39;%20kidney%20function." target="_blank" rel="noopener noreferrer nofollow">Felzartamab Shows Promise in Reducing Proteinuria in IgA Nephropathy</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Felzartamab, a monoclonal antibody, demonstrates significant potential in reducing proteinuria in patients with IgA nephropathy. This Phase 2 clinical trial highlights its ability to deplete disease-causing antibodies, offering a promising long-term therapeutic option without the need for continuous dosing. These findings suggest that felzartamab could provide sustained benefits, improving patient outcomes in managing IgA nephropathy.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.hcplive.com/view/long-term-options-for-igan-management-with-jonathan-barratt-md-phd?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">IgA Nephropathy Management: New Long-term Treatment Insights</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Management of IgA nephropathy (IgAN) has progressed with new long-term treatment options, such as Nefecon, which has demonstrated effectiveness in reducing proteinuria. Dr. Jonathan Barratt discusses the long-term benefits of this treatment, emphasizing its sustained impact even after a treatment break. These insights provide nephrologists with valuable guidance in developing extended treatment plans for IgAN patients, offering new hope for managing the disease over time.</span></p></td></tr></table></div></div><div class="image"><img alt="" class="image__image" style="border-radius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-sizing:border-box;border-color:#E5E7EB;" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9b6578ae-a61b-40f5-998f-8b9a29feccf5/Icon_Blue.png?t=1726247509"/></div><p class="paragraph" style="text-align:center;"><span style="font-size:0.6rem;">Health Spotlight’s IgA Nephropathy is a </span><span style="font-size:0.6rem;"><a class="link" href="https://www.contentive.com/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Contentive</a></span><span style="font-size:0.6rem;"> publication in the </span><span style="color:rgb(99, 32, 238);font-size:0.6rem;">Healthcare</span><span style="font-size:0.6rem;"> division</span></p></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=beec9e0e-901f-498b-ac9c-154702b1c57d&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>Weekly Spotlight - 31.10.24</title>
  <description>Biogen&#39;s Phase 2 Success, Oxford Classification for Pediatric Outcomes, and Nefecon&#39;s Long-term Management Potential.</description>
  <link>https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-31-10-24</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-31-10-24</guid>
  <pubDate>Thu, 31 Oct 2024 18:00:00 +0000</pubDate>
  <atom:published>2024-10-31T18:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><p class="paragraph" style="text-align:center;"><a class="link" href="https://iga-nephropathy.healthspotlight.io/subscribe?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Subscribe</a> | <a class="link" href="{{rp_referral_hub_url}}" target="_blank" rel="noopener noreferrer nofollow">Share with your community</a></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>In the News</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://endpts.com/biogens-full-ph2-data-for-iga-nephropathy-drug-sanofi-invests-in-obesity-biotech/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Biogen&#39;s Phase 2 Success in IgA Nephropathy Drug Development</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Biogen&#39;s Phase 2 trial data for felzartamab highlights its potential to positively impact IgA nephropathy treatment. This promising development joins Biogen&#39;s portfolio of treatments advancing kidney care, while Sanofi&#39;s parallel investment in obesity biotech signals broader patient-focused initiatives in chronic disease management.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.tandfonline.com/doi/full/10.1080/0886022X.2024.2411846?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Oxford Classification Predicts IgA Nephropathy Outcomes in Children</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">A new study supports the Oxford Classification as a predictive tool for kidney outcomes in children with IgA nephropathy, particularly noting specific lesions (M, S, T, C) associated with poorer prognoses. This classification aids physicians in personalising treatment strategies and improving patient care for paediatric IgA nephropathy.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.hcplive.com/view/long-term-options-for-igan-management-with-jonathan-barratt-md-phd?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Long-term Options for IgA Nephropathy Management</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Jonathan Barratt discusses Nefecon&#39;s efficacy in long-term IgA nephropathy management, with promising outcomes for re-dosing protocols. The open-label study shows sustained reduction in proteinuria without safety issues, providing hope for lasting symptom control and improved quality of life for patients with IgA nephropathy.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.healthcentral.com/video/kidney-disease/really-honest-answers-rare-kidney-disease-stress-management?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Coping Strategies for Stress in Rare Kidney Disease Patients</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Ginger Murphy shares her journey with rare kidney disease, highlighting stress as a major factor. She manages it through yoga, walking, and spending time with grandkids. Stress impacts her health, but she finds relief in emotional release and relaxation techniques, maintaining a positive outlook despite challenges.</span></p></td></tr></table></div></div><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Community</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://forms.office.com/e/kEtaEqnVKA?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">We want to hear your story!</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!</span></p></td></tr></table></div></div><div class="image"><img alt="" class="image__image" style="border-radius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-sizing:border-box;border-color:#E5E7EB;" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9b6578ae-a61b-40f5-998f-8b9a29feccf5/Icon_Blue.png?t=1726247509"/></div><p class="paragraph" style="text-align:center;"><span style="font-size:0.6rem;">Health Spotlight’s IgA Nephropathy is a </span><span style="font-size:0.6rem;"><a class="link" href="https://www.contentive.com/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Contentive</a></span><span style="font-size:0.6rem;"> publication in the </span><span style="color:rgb(99, 32, 238);font-size:0.6rem;">Healthcare</span><span style="font-size:0.6rem;"> division</span></p></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=b383e101-675b-427d-9641-8a4aa9e52a09&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

      <item>
  <title>Weekly Spotlight - 24.10.24</title>
  <description>Significant funding milestones for IgA nephropathy gene therapy and, innovative predictive tools for paediatric care</description>
  <link>https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-24-10-24</link>
  <guid isPermaLink="true">https://iga-nephropathy.beehiiv.com/p/weekly-spotlight-24-10-24</guid>
  <pubDate>Thu, 24 Oct 2024 17:00:00 +0000</pubDate>
  <atom:published>2024-10-24T17:00:00Z</atom:published>
    <dc:creator>Liam Ball</dc:creator>
  <content:encoded><![CDATA[
    <div class='beehiiv'><style>
  .bh__table, .bh__table_header, .bh__table_cell { border: 0px solid #e5ddff; }
  .bh__table_cell { padding: 5px; background-color: #f8f8f8; }
  .bh__table_cell p { color: #2D2D2D; font-family: 'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
  .bh__table_header { padding: 5px; background-color:#f8f8f8; }
  .bh__table_header p { color: #011053; font-family:'Roboto',-apple-system,BlinkMacSystemFont,Tahoma,sans-serif !important; overflow-wrap: break-word; }
</style><div class='beehiiv__body'><p class="paragraph" style="text-align:center;"><a class="link" href="https://iga-nephropathy.healthspotlight.io/subscribe?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Subscribe</a> | <a class="link" href="{{rp_referral_hub_url}}" target="_blank" rel="noopener noreferrer nofollow">Share with your community</a></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>In the News</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.pharmaceutical-technology.com/news/purespring-secures-105m-to-start-phase-i-ii-trial-of-igan-gene-therapy/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Purespring Advances Gene Therapy for Kidney Disease with £105m Funding</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Purespring Therapeutics has secured £105m to advance its lead candidate, PS-002, into Phase III trials for IgA nephropathy, a kidney disease. This gene therapy targets podocytes to address protein leakage and kidney dysfunction. The funding, led by Sofinnova Partners, supports Purespring&#39;s innovative treatment platform.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.sciencedirect.com/science/article/pii/S0085253824006458?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">New Prediction Tool Enhances Care for Children with IgA Nephropathy</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">The updated International IgA Nephropathy Prediction Tool for children enhances care by accurately predicting kidney disease progression. This tool, tailored for paediatric use, improves risk assessment and treatment planning, offering hope for better outcomes. Its development underscores the importance of precise, compassionate healthcare for young patients.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.tandfonline.com/doi/abs/10.1080/13543784.2024.2414902?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Sparsentan: A New Hope for IgA Nephropathy Treatment</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Sparsentan, a dual endothelin and angiotensin receptor antagonist, offers hope for IgA nephropathy treatment. It significantly reduces proteinuria without harming renal function, as shown in the PROTECT study. This promising therapy, approved by the FDA, could improve outcomes for patients at high risk of disease progression.</span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.nature.com/articles/s41581-024-00885-3?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">IgA Nephropathy: Pathogenesis and Emerging Treatment Strategies</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">IgA nephropathy (IgAN) is a leading cause of chronic kidney disease, with a complex pathogenesis involving galactose-deficient IgA1 and immune complex formation. Recent advances highlight genetic and immune factors, with emerging therapies targeting mucosal B cells, cytokines, and complement pathways, offering hope for improved patient outcomes.</span></p></td></tr></table></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Digital Innovation in the NHS</b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:rgb(61, 128, 245);"><b><a class="link" href="https://www.theguardian.com/society/2024/oct/21/wes-streeting-unveils-plans-for-patient-passports-to-hold-all-medical-records?utm_source=als.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Digital Patient Passports to Revolutionise NHS Healthcare</a></b></span></p></td></tr><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:left;"><span style="color:black;font-family:Aptos Narrow, sans-serif;">Wes Streeting, the health secretary, has unveiled an ambitious plan to r</span><span style="color:black;font-family:Aptos Narrow, sans-serif;"><b>evolutionise healthcare in the UK by introducing patient passports</b></span><span style="color:black;font-family:Aptos Narrow, sans-serif;">, which will digitally store all NHS medical records in one accessible location. This transformative initiative aims to enhance patient care by allowing </span><span style="color:black;font-family:Aptos Narrow, sans-serif;"><b>swift access to health data for GPs, hospitals, and ambulance services</b></span><span style="color:black;font-family:Aptos Narrow, sans-serif;">, thereby reducing repeat tests and medication errors. The digital data bill will standardise information systems across the NHS, creating a </span><span style="color:black;font-family:Aptos Narrow, sans-serif;"><b>unified patient record on the NHS app</b></span><span style="color:black;font-family:Aptos Narrow, sans-serif;">. </span><br><br><span style="color:black;font-family:Aptos Narrow, sans-serif;">Despite the potential benefits,</span><span style="color:black;font-family:Aptos Narrow, sans-serif;"><b> concerns about privacy and data security have been raised</b></span><span style="color:black;font-family:Aptos Narrow, sans-serif;">. Critics, including </span><span style="color:black;font-family:Aptos Narrow, sans-serif;"><b>medConfidential</b></span><span style="color:black;font-family:Aptos Narrow, sans-serif;">, warn that the centralised database could become a target for hackers and misuse by unauthorised personnel. Public scepticism is evident, with a significant portion of the population expressing distrust in the NHS&#39;s ability to keep data secure. </span><br><br><span style="color:black;font-family:Aptos Narrow, sans-serif;">Streeting, however, remains optimistic, emphasising the collaboration with tech and pharma companies to develop new treatments and ensure the NHS benefits from cutting-edge advancements. </span><span style="color:black;font-family:Aptos Narrow, sans-serif;"><b>He assures that patient data will be protected and anonymised</b></span><span style="color:black;font-family:Aptos Narrow, sans-serif;">, addressing fears of &quot;big brother&quot; oversight. The government is also focusing on shifting healthcare from hospitals to community-based centres and prioritising prevention over treatment, with plans to distribute wearable tech for health monitoring. </span><br><br><span style="color:black;font-family:Aptos Narrow, sans-serif;">This bold vision for the NHS seeks to </span><span style="color:black;font-family:Aptos Narrow, sans-serif;"><b>harness the power of digital innovation to improve healthcare delivery</b></span><span style="color:black;font-family:Aptos Narrow, sans-serif;">, but it must navigate the delicate balance between technological advancement and patient privacy.</span></p></td></tr></table></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Community Voices</b></span></p></td></tr></table></div><div class="embed"><a class="embed__url" href="https://www.linkedin.com/pulse/adventures-rosie-shared-care-record-mark-hindle-chlbe/?trackingId=O44xVJHAQH62FyijFYQj3w%3D%3D&utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank"><div class="embed__content"><p class="embed__title"> The adventures of Rosie and the shared care record </p><p class="embed__description"> It was a privilege to be able to share my perspective on the implementation of longitudinal health records in the NHS at the UNGA Digital Health Symposium in New York today. I told the story of Rosie, my niece, an incredible young person who is affected by the inability of the NHS to share data and </p></div></a></div></div><p class="paragraph" style="text-align:left;"></p><div class="section" style="background-color:#f8f8f8;border-color:#222222;border-radius:5px;border-style:solid;border-width:0.5px;margin:5.0px 5.0px 5.0px 5.0px;padding:5.0px 5.0px 5.0px 5.0px;"><div style="padding:14px 15px 14px;"><table class="bh__table" width="100%" style="border-collapse:collapse;"><tr class="bh__table_row"><td class="bh__table_cell" width="100%"><p class="paragraph" style="text-align:center;"><span style="color:rgb(3, 153, 205);font-family:Aptos Narrow, sans-serif;font-size:18pt;"><b>Have Your Say</b></span></p></td></tr></table></div></div><div class="image"><img alt="" class="image__image" style="border-radius:0px 0px 0px 0px;border-style:solid;border-width:0px 0px 0px 0px;box-sizing:border-box;border-color:#E5E7EB;" src="https://media.beehiiv.com/cdn-cgi/image/fit=scale-down,format=auto,onerror=redirect,quality=80/uploads/asset/file/9b6578ae-a61b-40f5-998f-8b9a29feccf5/Icon_Blue.png?t=1726247509"/></div><p class="paragraph" style="text-align:center;"><span style="font-size:0.6rem;">Health Spotlight’s IgA Nephropathy is a </span><span style="font-size:0.6rem;"><a class="link" href="https://www.contentive.com/?utm_source=iga-nephropathy.healthspotlight.io&utm_medium=Weekly_Newsletter&utm_campaign=Heme_NIAB_Campaign" target="_blank" rel="noopener noreferrer nofollow">Contentive</a></span><span style="font-size:0.6rem;"> publication in the </span><span style="color:rgb(99, 32, 238);font-size:0.6rem;">Healthcare</span><span style="font-size:0.6rem;"> division</span></p></div><div class='beehiiv__footer'><br class='beehiiv__footer__break'><hr class='beehiiv__footer__line'><a target="_blank" class="beehiiv__footer_link" style="text-align: center;" href="https://www.beehiiv.com/?utm_campaign=12fa3b3b-c7a9-4ab8-a155-a3f25dbcf149&utm_medium=post_rss&utm_source=iga_nephropathy_insights">Powered by beehiiv</a></div></div>
  ]]></content:encoded>
</item>

  </channel>
</rss>
